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Onkogene KrasG12D-Expression transformiert adulte Azinuszellen irreversibel in 
duktale Zellen. Die sogenannte azinär-duktale Metaplasie (ADM) ist entscheidend bei 
der Entwicklung des duktalen Pankreaskarzinoms (PDAC). Jüngste Studien zeigen, 
dass diese metaplastische Veränderung eine spezielle Umlagerung des Zytoskeletts 
erfordert, welche wiederum eine Umverteilung der apiko-basalen Spannung innerhalb 
der Azinuszellen erzeugt. Der genaue Mechanismus für diese apiko-basale 
Spannungsumverteilung ist jedoch noch unbekannt. mTOR (mechanistisches Ziel der 
Rapamycinkinase), eine Zielstruktur von onkogenem Kras, beruht auf der Funktion von 
Rptor (regulatorisch assoziiertes Protein von mTOR, Komplex 1) und Rictor (RPTOR-
unabhängiger Begleiter von mTOR, Komplex 2), um die mutmaßlichen PDAC-
onkogenen Komplexe, mTORC1 und mTORC2, zu bilden. Der Actin-verwandte 
Protein 2/3 (Arp2/3) -Komplex ist ein Actin-Keimbildner, der die neuartige Actin-
Polymerisation und die Erzeugung mechanischer Spannungen in anderen biologischen 
Zusammenhängen fördert. 
 
Ein gut etabliertes Mausmodell der entzündungsbeschleunigten KrasG12D-gesteuerten 
frühen Pankreaskarzinogenese wurde verwendet. Ebenfalls wurden Rptor und Rictor in 
Azinuszellen spezifisch ausgeschaltet, um mTORC1 und mTORC2 zu deaktivieren, 
während Arpc4 (Aktin-verwandte Protein 2/3 Komplexuntereinheit 4) deletiert wurde, 
um die Funktion des Arp2/3-Komplex zu verhindern. Ein 3D-Kultursystem wurde 
appliziert, um die ADM-Bildung in vitro zu untersuchen. Die Ergebnisse der 
präklinischen Modelle wurden an menschlichen Materialien bestätigt. 
Massenspektrometrische Proteomanalyse wurde zum Screening auf nachgeschaltete 
Ziele von mTORC1 und mTORC2 verwendet. 
 
Sowohl mTORC1 als auch mTORC2 sind insbesonders in ADM-Läsionen bei 
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Menschen und Mäusen aktiviert. Funktionell hemmt die alleinige Deaktivierung von 
mTORC1 oder mTORC2 nur vorübergehend die onkogene KrasG12D-gesteuerte ADM-
Bildung. Eine gleichzeitige Deaktivierung von mTORC1 und mTORC2 ist erforderlich, 
um die onkogene KrasG12D-gesteuerte ADM-Entwicklung dauerhaft zu unterdrücken. 
Somit existiert eine synergistische Wechselwirkung zwischen ihnen. Die 
Proteomanalysen identifizieren Arp2/3-Komplex als den gemeinsamen 
nachgeschalteten Effektor von mTORC1 und mTORC2. Die genetische Deaktivierung 
des Arp2/3-Komplexes blockiert die onkogene KrasG12D-gesteuerte ADM-Entwicklung 
vollständig und ahmt den Phänotyp von Mäusen, bei denen sowohl mTORC1 als auch 
mTORC2 fehlen, nach. Insbesondere KrasG12D-Azinuszellen mit deaktiviertem Arp2/3-
Komplex sind nicht in der Lage, eine apiko-basale Spannungsumverteilung zu erzeugen. 
Mechanistisch gesehen ist mTORC1 für die direkte Proteinsynthese von Rac1 (kleine 
GTPase 1 der Rac-Familie) und Arp3 verantwortlich, während mTORC2 die Aktivität 
des Arp2/3-Komplexes durch Akt / Rac1-Signalübertragung fördert. 
 
Nun identifizieren wir eine gleichzeitige, jedoch nicht redundante regulatorische Rolle 
von mTORC1 und mTORC2 bei der Förderung der Arp2/3-Komplexfunktion, die für 
die KrasG12D-gesteuerte ADM-Bildung unverzichtbar ist. Die durch den Arp2/3-
Komplex vermittelte Aktinpolymerisation ist für die Erzeugung einer Umverteilung der 























Upon oncogenic KrasG12D expression, adult acinar cells assume an irreversible 
phenotype of acinar-to-ductal metaplasia (ADM), playing a crucial role in pancreatic 
ductal adenocarcinoma (PDAC) development. Recent studies demonstrate that this 
metaplastic change requires a specific cytoskeleton rearrangement generating apical-
basal tension redistribution within acinar cells. However, the exact mechanism for this 
apical-basal tension redistribution is still unknown. mTOR (mechanistic target of 
rapamycin kinase), a downstream target of oncogenic Kras, relies on the function of 
Rptor (regulatory associated protein of mTOR, complex 1) and Rictor (RPTOR 
independent companion of mTOR, complex 2) to form putative oncogenic complexes 
of PDAC: mTORC1 and mTORC2. The actin-related protein 2/3 (Arp2/3) complex is 
an actin nucleator promoting novel actin polymerization and generation of mechanical 
tension in other biological contexts.  
 
A well-established mouse model of inflammation-accelerated KrasG12D-driven early 
pancreatic carcinogenesis was used. At the same time, Rptor and Rictor were 
conditionally ablated in acinar cells to deactivate mTORC1 and mTORC2, while Arpc4 
(actin related protein 2/3 complex subunit 4) was deleted to ablate the function of 
Arp2/3 complex. A 3D-culture system was applied to investigate ADM formation in 
vitro. Results from the preclinical models were confirmed on human materials. Mass 
spectrometry-based proteomic analysis was used for screening downstream targets of 
mTORC1 and mTORC2. 
 
Both mTORC1 and mTORC2 are mainly activated in human and mouse ADM lesions. 
Functionally, mTORC1 or mTORC2 deactivation alone only transiently inhibits 
oncogenic KrasG12D-driven ADM formation. A dual deactivation of mTORC1 and 
mTORC2 is required to persistently suppress oncogenic KrasG12D-driven ADM 
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development, demonstrating a synergistic interaction between them. The proteomic 
analyses identify the Arp2/3 complex as the common downstream effector of mTORC1 
and mTORC2. Genetic deactivation of Arp2/3 complex completely blocks oncogenic 
KrasG12D-driven ADM development in mice, photocopying the phenotype of mice 
deficient for both mTORC1 and mTORC2. In particular, KrasG12D acinar cells with 
deactivated Arp2/3 complex are not capable of generating apical-basal tension 
redistribution. Mechanistically, mTORC1 is responsible for the direct protein synthesis 
of Rac1 (Rac family small GTPase 1) and Arp3 while mTORC2 promotes the activity 
of Arp2/3 complex by Akt/Rac1 signalling.  
 
Now, we identify a dual, yet non-redundant, regulatory role of mTORC1 and mTORC2 
in promoting Arp2/3 complex function, which is indispensable for KrasG12D-driven 
ADM formation. The Arp2/3 complex-mediated actin polymerization is responsible for 
generating apical-basal tension redistribution, acting as an “incipient” instruction cue 
for ductal morphology of acinar cells. 






1.1 Pancreatic ductal adenocarcinoma  
 
Pancreas cancer is highlighted by a similar morbidity and mortality.1 Though surgical 
resection leads to more prolonged survival compared with chemotherapy, radiation 
therapy and palliative care, only a small part of patients are eligible for curative 
resection due to the late diagnosis.2 Furthermore, a majority of patients succumb to 
recurrence in the end.1, 3, 4 Total deaths due to pancreas cancer are predicted to increase 
dramatically to become one of the top cancer killers before 2030 in the USA.5 Early 
diagnosis and treatment of pancreatic cancer is the only way to reduce mortality. 
 
Pancreatic ductal adenocarcinoma (PDAC) is the most common entity of malignant 
pancreatic tumours, which also include solid-pseudopapillary neoplasms (SPNs), 
pancreatic neuroendocrine tumours (PanNETs), acinar cell carcinomas (ACC), 
pancreatoblastomas, classified according to tumour morphology and 
immunohistochemical features.6, 7 Risk factors for PDAC consist of cigarette smoking, 
chronic pancreatitis, diabetes, obesity, races and inherited risk factors.8 But the most 
vital driver factor of PDAC is gene alteration, generally including genetic mutations in  
kirsten rat sarcoma viral oncogene homolog (KRAS), cyclin-dependent kinase inhibitor 
2A (CDKN2A), tumor protein p53 (TP53) and small mothers against decapentaplegic 
(SMAD4).9 KRAS is the most universal mutated oncogene, usually co-exists with 
genetic alternations on putative tumour suppressers such as CDKN2A, TP53 and 
SMAD4.7, 10, 11 There are three well-established PDAC precursor lesions: pancreatic 
intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), 
and mucinous cystic neoplasms (MCNs).12 Every precursor lesion is different from 
each other with their unique features in pathology. 
 
In the adult pancreas, more than 90% of it are acinar cells, and the rest are ductal and 
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endocrine cells, including α, β, δ, PP and ɛ cells.13 It was thought that PDAC originates 
from ductal cells in the pancreas because of their similar morphologies. Recently, 
results from genetically engineered mouse models (GEMMs) revealed that PDAC can 
be initiated from different cell types in the pancreas.14 Lineage tracing studies 
demonstrate that PanIN lesions mainly arise from the acinar cell.15 However, IPMNs 
might develop from the ductal epithelium within the so-called progenitor niche; the 
origin of MCN is still unknown.14 Thus, the cell of origin for PDAC remains elusive. It 
was reported that insulin-expressing cells could also be transformed to develop PanINs 




1.2 GEMM of PDAC 
1.2.1 KrasG12D mouse model 
To identify the molecular mechanism of initiation and development of pancreatic cancer, 
develop novel diagnostic and therapeutic strategies, GEMMs are employed to 
recapitulate several pancreatic tumour subtypes. In GEMMs of PDAC, a so-called 
“KrasG12D strain” was used as the backbone mouse model (see below). This mouse 
model relies on the Lox-Stop-Lox-KrasG12D mouse strain (referred to as LSL-KrasG12D) 
and the Cre recombinase-dependent tissue-specific system. In the LSL-KrasG12D mouse, 
the expression of knock-in mutant KrasG12D allele is blocked by STOP cassette flanked 
by LoxP sites. In the presence of Cre recombinase driven by Pdx1 or Ptf1a (also known 
as p48), the pancreas-specific promoter, mutant Kras is activated by removing STOP 
cassette and by Cre recombinase. These mice developed precursor lesions and partially 
progressed to PDAC after a long latency. Based on the KrasG12D mouse model, one of 
the most used GEMMs of PDAC was generated by crossing with the LSL-Trp53R172H 
mouse strain. It displayed invasive and metastatic carcinomas.17, 18  
1.2.2 Inducible system 
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However, there is a limitation of these mouse models. The Cre-mediated recombination 
occurs in embryo, which means Kras is activated in a very early stage, the pancreas 
develops PanINs rapidly after birth, which is different from the PDAC development in 
humans. Here, PDAC occurs in the mature gland of adult subjects through random 
mutations in the pancreas. To overcome these shortcomings, an inducible system was 
developed in which genes of interest can be knocked in or knocked out temporally and 
spatially. As such, one of frequently used system is CreER technology which was firstly 
described by Feil et al. in 1996. In this new version of the Cre-loxp system, Cre 
recombinase is fused to a mutated ligand-binding domain (LBD) of the human estrogen 
receptor (ER), which is so-called CreER. The CreER recombinase can be activated by 
tamoxifen instead of estradiol in vivo.19 Once induced by tamoxifen, CreER 
recombinase translocates from the cytoplasm into the nucleus, where it mediates the 
genetic recombination of LoxP sites.20 Currently, the most effective CreER 
recombinase is CreERT2 version. The LBD of CreERT2 harbours 
G400V/M543A/L544A triple mutations to avoid possible unexpected side effects 
induced by tamoxifen21, 22 In the field of PDAC modelling, the inducible systems 
include ElastasCreERT2, Ptf1aCre-ERTM, and Pdx1-CreERT,23-25 where the CreER 
recombinase expression is driven by cell-type-specific promotors in pancreas. To 
monitor the recombination efficiency of these inducible systems, a reporter gene has 
been developed and used as a critical tool. The most widely used reporters are 
autofluorescent proteins (AFPs), such as green fluorescent protein (GFP) and red 
fluorescent protein (RFP). The expression of AFPs can be detected by fluorescence-
activated cell sorting (FACS) at the single living cell level, fluorescence microscopy 
and fluorometer without any invasive treatment and exogenous substrates. The 
ubiquitous expression of AFPs can be achieved by inserting the reporter gene into the 
Rosa26 locus, which is transcriptionally active across the majority of organs. The 
temporal and tissue-specific expression of Rosa26-targeted reporter proteins can be 
realized by the Cre-loxp system using the above mentioned Loxp_Stop_Loxp 
strategy.26 
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1.3 Acinar-to-ductal metaplasia 
 
In the pancreas, acinar cells are highly plastic which have the potential of 
dedifferentiating to other cell types such as ductal cells and endocrine cells.15, 27. The 
acinar-to-ductal metaplasia (ADM) is a process that acinar cells acquire a duct-like 
phenotype.28 In vivo, ADM can be induced by oncogenic Kras and pancreatitis.29 In 
vitro, the factors that are applied to promote ADM formation include mutant Kras,30 
transforming growth factor-α (TGF-α), hepatocyte growth factor (HGF) in rodent31 and 
transforming growth factor-β (TGF-β) in human.32 During the process of ADM, gene 
expression profile changes dramatically. Part of genes are downregulated, such as Ptf1a, 
Mist1, Gata6. These are transcription factors which maintain the morphology and 
functions of acinar cells. Genetic ablation of any of these genes in acinar cells leads to 
ADM formation.33-35 Other genes like p120 catenin, an intracellular protein, which 
supports cell-cell adhesion, its deletion in the pancreas lead to ADM formation.36 Part 
of genes are upregulated. Transcription factors Sox9 and Pdx1 are required for acinar 
cell dedifferentiation. Sox9 mainly expresses in human and mouse centroacinar cells, 
also in acinar cells and some ductal cells, but at a low level.37, 38 In the context of 
inflammation, Sox9 expression increased dramatically in acini which proceed to 
ADM.39 The expression of Pdx1 is mostly in islets, but few in acinar cells of adult 
mouse pancreas, in pancreatitis, Pdx1 is upregulated.40, 41 Furthermore, the sustained 
Pdx1 expression in acinar cells induced also ADM phentype.42 Besides, the matrix-
degrading metalloproteinases (MMP)-9 was strongly upregulated in the inflamed 
pancreas. Inflammatory macrophages secret several cytokines to activate nuclear factor 
(NF)-κB, which regulates the degradation of the extracellular matrix through MMP-9. 
It is proved that the MMP inhibitor completely blocked the pancreatitis-induced ADM 
formation in vivo.43  
 
 
1.4 Pancreatic regeneration 
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ADM is common after acute pancreatitis or injury. In wild-type animals, ADM 
formation is a transient process that resolves itself in 7 days post caerulein treatment. 
During this process, pancreatic regeneration is achieved by ADM redifferentiation and 
acinar cell proliferation.44-46 Some genes are essential for pancreas regeneration; for 
example, Hes1 is expressed in the centroacinar cells; the loss of Hes1 leads to persistent 
ADM after acute caerulein-induced pancreatitis.47 Knock out of ARID1A, which 
altered most frequently in PDAC, leads to impaired recovery of the exocrine 
compartment.48 Hedgehog (Hh) pathway maintains progenitor cell number in adult 
tissues, genetic inhibition of Hh Signaling results in impaired pancreatic regeneration.49 
Numb, a multifunctional protein, is vital for cell division and maintaining progenitor 
cell. Deletion of Numb in pancreatic acinar cells leads to abundant duct structures 7 
days post caerulein injection.45  
 
 
1.5 ADM driven by oncogenic KrasG12D 
 
In the presence of KrasG12D, ADM lesions do not differentiate back to acinar cells, but 
they further progress into pre-neoplastic lesions and eventual PDAC. This is mediated 
by a number of downstream pathways of oncogenic KrasG12D (see below). 
1.5.1 MAPK pathway 
Mitogen-activated protein kinase (MAPK) pathway is well studied as a downstream 
pathway of Kras. It regulates cell growth, proliferation, differentiation and other 
biological processes. The classical MAPK pathway is Ras → Raf → MEK → ERK; 
Firstly, the activated Kras phosphorylates the serine/threonine kinase Raf, continuously, 
MAPK kinase (MEK1/2) is activated by Raf, which proceeds on phosphorylating 
extracellular signal-regulated kinase (ERK1/2).50 In wild-type mice, the MAPK 
pathway is upregulated but only for a short time during acute pancreatitis, in the context 
of oncogenic KrasG12D, the upregulation is consistent. A pharmacological inhibition of 
MAPK signalling prevents the ADM and PanIN formation in KrasG12D mice 1 week 
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after caerulein injection. Interestingly, under the inhibition of Mek1/2, PanIN lesions 
are capable of redifferentiating back to acinar cells.51 Above all, the sustained activation 
of MAPK pathway is partially accountable for ADM, PanIN and PDAC development 
caused by oncogenic KrasG12D and pancreatitis.    
1.5.2 PI3K pathway 
Phosphoinositide 3-kinase (PI3K) is another downstream effector of Kras. It is proved 
in mice that PI3K p110α isoform is activated in pancreatic precursor lesion induced by 
oncogenic KrasG12D and pancreatitis. A pharmacological inhibition of p110α block the 
ADM formation in vivo. Moreover, the genetic inactivation of p110α prevents the 
formation of pre-neoplastic lesion in these models. Further analysis revealed that the 
p110α signalling regulates the ADM plasticity through actin cytoskeleton.29 
Consistently, Payne SN et al. proved the similar finding, he generated a Pc1Pik3cap110* 
mouse model in which PI3K signalling is persistently activated, and observed that this 
persistently activated PI3K signalling accelerated the ADM development in vivo. 
ERK1/2, the downstream of PI3K, is involved in such process.52 Sustained activation 
of Akt signalling, the downstream of PI3K, drives the formation of “ductal structures”: 
a portion of these ductal structures is the result of proliferative ductal epithelium, ADM 
lesions and β cells also contribute partially to these “ductal structures”. 53 Rac family 
small GTPase 1 (Rac1), a guanosine triphosphatase (GTPase) of rhodopsin (Rho) 
family, is also a downstream effector of PI3K, regulating actin dynamics. It is proposed 
that the deactivation of PI3K pathway and the Rac1 ablation prevent the KrasG12D-
driven ADM development in vivo by affecting the similar cellular machinery-actin 
remodelling.54  
1.5.3 Other pathways 
Other upregulated signalling pathways include polycystic kidney disease 1 (PKD1), 
Notch and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). It 
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was reported that the expression of oncogenic Kras cause san oxidative stress in ADM 
and PanIN leions. In 3D culture, the pharmacological inhibition of mitochondrial 
reactive oxygen species (mROS) reduced the capacity of isolated KrasG12D acinar cells 
in promoting ADM lesions in vitro. The further study revealed that mROS activated 
PKD1, which triggers the NF-κB pathway. Collectively, it led to the increased 
expression of epidermal growth factor receptor (EGFR) and its ligands TGF-α and a 
disintegrin and metalloptroteinase-17 (ADAM 17).55 In vitro data from the same 
researchers proved that TGF-α induced ADM formation through Kras activation, PKD1 
is activated as a downstream target of Kras, however, inhibition of Notch pathway block 
ADM formation under activated TGF-α-Kras-PKD1 signalling.56 In another study, the 
TGFα-induced ADM relies on the function of matrix metalloproteinase (MMP) 7, 
which is important in maintaining the pro-ADM function of Notch signalling vitro.57  
 
 
1.6 Pancreatic injury 
 
Oncogenic KrasG12D promotes ADM and PanIN formation in mouse model, however 
few of them develop PDAC, to accelerate this procedure, extra events are required.  
Such additional events include mutation of p53,58 CDKN2A,59 inactivations of 
Smad4.60  
 
The widely used method to accelerate oncogenic Kras-driven pancreatic carcinogenesis 
is the caerulein-induced pancreatitis. Caerulein, an analogue of cholecystokinin (CCK), 
stimulates the secretion of digestive enzymes in rodents, resulting in the severe 
autodigestion by pancreatic protease.61 According to the commonly used protocol for 
acute pancreatitis induction, mice are administered caerulein at supramaximal levels, 
seven doses hourly one day, 50 μg/kg body weight, but in pancreatic regeneration 
research, two consecutive days intraperitoneal injection are required.62, 63 However, in 
the presence of oncogenic KrasG12D, the organ regeneration in acinar cell compartment 
is blocked, instead, the acinar cell acquired non-reversible ADM phenotype and some 
of them further progress into PanIN lesions and PDAC after caerulein-induced 




1.7 mTOR signalling 
 
Mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase which 
belongs to the PI3K-related kinase (PIKK) family. mTOR is involved in two complexes, 
mTOR complex 1 (mTORC1) and 2 (mTORC2), which play crucial roles in growth, 
metabolism and disease. 
1.7.1 mTORC1 signalling 
Components of mTORC1 
mTORC1 is composed of mTOR, the regulatory-associated protein of mTOR (Rptor), 
mammalian lethal with Sec13 protein 8 (mLST8, also known as GβL),65, 66 proline-rich 
Akt substrate of 40 kDa (PRAS40)67, 68 and DEP domain-containing mTOR-interacting 
protein (DEPTOR).69 Rptor is required for mTORC1 kinase activity.70, 71 mLST8 keeps 
the kinase activation loop stable.72 However, the other two subunits play an inhibitory 
role in the signalling.  
 
Figure 1. The simplified structure of mTORC1 
 
mTORC1 upstreams 
mTORC1 is activated by the small GTPase ras homolog enriched in brain (Rheb),73 
which is the downstream effector of Tuberous Sclerosis Complex (TSC). Many growth 
factor pathways such as insulin/insulin-like growth factor-1 (IGF-1) pathway, receptor 
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tyrosine kinase-dependent Ras signalling, Wnt signalling and the inflammatory 
cytokine TNFα activate mTORC1 via phosphorylating TSC.74 For example, insulin 
promotes the PI3K activity that converts phosphatidylinositol 4,5-bisphosphate (PIP2) 
to phosphatidylinositol 3,4,5 trisphosphate (PIP3). By the function of PIP3, Akt is 
recruited to the plasma membrane where it is phosphorylated by pyruvate 
dehydrogenase kinase 1 (PDK1) at Thr308, leading to the partial activation of Akt This 
partially activated Akt, in turn, phosphorylates TSC2, which further activate the 
mTORC1.75 
 
mTORC1 signalling is inhibited under the circumstances of glucose deprivation, 
hypoxia and DNA damage through either the direct phosphorylation of Rptor or the 
indirect activation of TSC.76-78 mTORC1 is also tightly regulated by the concentration 
of amino acid. It was reported that Rag GTPases could be converted to be activated 
state once stimulated by amino acids, which allows them to bind to Rptor, then 
mTORC1 is recruited to the lysosomal surface and activated by Rheb. This discovery 
was considered as a breakthrough by unraveling the mechanism underlying amino acid 
sensing by mTORC1.79, 80  
 
mTORC1 downstream 
p70S6 Kinase 1 (S6K1) and eIF4E Binding Protein (4EBP) are two main downstream 
targets of mTORC1. S6K1 is phosphorylated by mTORC1 on Thr 389 and further 
phosphorylated by PDK1. Activated S6K1 subsequently phosphorylates eukaryotic 
translation initiation factor 4B (eIF4B) to promote the mRNA translation initiation. At 
the meantime, it also phosphorylates programmed Cell Death 4 (PDCD4), an inhibitor 
of eIF4B, to accelerate the degradation of PDCD4.81, 82 The 40S ribosomal protein S6 
(S6) can also be phosphorylated by S6K1, it is linked to the mRNA translation and cell 
growth.83 The other substrate-4EBP binds to eukaryotic translation initiation factor 4E 
(eIF4E), as such, it prevents the assembly of Eukaryotic initiation factor 4F (eIF4F) 
complex. When phosphorylated by mTORC1, 4EBP dissociates from eIF4E, promoting 
the mRNA translation initiation.84 mTORC1 promotes the protein synthesis mainly 
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through these two key effectors. 
 
mTORC1 also activates the sterol responsive element binding protein (SREBP) which 
is a transcription factor regulating the expression of metabolic proteins associated with 
fatty acid and cholesterol biosynthesis.85 S6K1 can activate carbamoyl-phosphate 
synthetase (CAD), which governs the pyrimidine synthesis pathway.86 mTORC1 also 
regulates the transcription factor hypoxia-inducible factor 1 (HIF1α), which promote 
the glucose metabolism by increasing the expression of glycolytic enzymes.87 Thus, 
mTORC1 signalling activates lipid, nucleotideand glucose metabolism to support cell 
growth. 
 
Unc-51-like kinase 1 (ULK1) can also be phosphorylated by mTORC1 when the 
nutrient is sufficient. This phosphorylation of ULK1 prevents the initiation of 
autophagy.88 Transcription factor EB (TFEB) can also be phosphorylated by mTORC1, 
which inhibits the process of autophagy.89, 90 In this way, mTORC1 promotes cell 
growth via the inhibition of protein catabolism. 
1.7.2 mTORC2 signalling 
Components of mTORC2 
mTORC2 shares the component of mTOR, mLST8 and DEPTOR with mTORC1. 
However, mLST8 is required to maintain the rictor-mTOR binding instead of the rptor-
mTOR interaction.91 Rapamycin insensitive companion of mTOR (Rictor) is specific 
to mTORC2, and it is essential for its activity.92 mTORC2 also contains the unique 
regulatory subunits of mammalian stress-activated protein kinase interacting protein 1 
(mSin1) and protein observed with rictor 1 and 2 (Protor1/2).93, 94  
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Figure 2. The simplified structure of mTORC2 
 
mTORC2 upstream 
mTORC2 is the downstream of insulin/PI3K signalling. One subunit of mTORC2 is 
mSin1 which has a pleckstrin homology (PH) domain. Via this PH domain, it interacts 
with mTOR kinase domain to prevent the activation of mTORC2, when insulin is not 
available. However, this inhibition can be released upon the SIN1-PH binding to PIP3 
(generated by PI3K) at plasma membrane.95 It is also reported that PI3K promotes the 
binding of mTORC2 to ribosomes, which are necessary for the mTORC2 activity; 
however, how ribosomes activate mTORC2 is elusive.96 mTORC2 can also be activated 
by phosphorylated Akt at T308, and this partial activation of Akt phosphorylates mSin1, 
which drives the mTORC2 activity.97  
 
mTORC2 downstream 
The first identified substrate of mTORC2 was protein kinase C alpha (PKCα), 
regulating the actin cytoskeleton.98 After that, it is reported that several other members 
of PKC protein kinase can also be phosphorylated by mTORC2, such as PKCδ, PKCζ, 
PKCγ and PKCε,99-101 involved in cytoskeleton organization and cell migration 
regulation. Another important downstream effector of mTORC2 is Akt.102 Akt is 
phosphorylated at Ser473 by mTORC2, leading to fully activated AKT signaling.103 
Furthermore, the serum- and glucocorticoid-induced protein kinase (SGK)1 is be 
activated by mTORC2 to regulate the ion transport and to promote cell survival.104 
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1.7.3 Physiological functions of mTOR signalling 
Both mTORC1 and mTORC2 are involved in various biological processes and they 
play essential roles in physiological procedures. Using well-established mouse models, 
more and more functions of these two mTOR complexes are being uncovered in 
mammalians. 
 
The regulation of mTORC1 signalling is critical for glucose homeostasis. The 
hyperactivation of mTORC1 in the liver inhibits autophagy and gluconeogenesis, 
resulting in hypoglycemia.105, 106 Sustained mTORC1 activity in the pancreas improves 
glucose tolerance at the beginning, but reduces β-cell mass and leads to hyperglycemia 
in the end.107, 108 mTORC1 signalling also promotes muscle growth. Activated 
mTORC1 signalling is correlated with muscle hypertrophy,109 impaired mTORC1 
signalling leads to severe muscle atrophy.110 Both mTORC1 and mTORC2 signalling 
play important roles in adipogenesis and lipid homeostasis. Inhibition of mTORC1 
blocks adipogenesis and suppresses lipogenesis in the adipocyte.111 mTORC2 
activation has been shown to accelerate lipogenesis in the liver.112 In the immune system, 
mTORC1 promotes T-cell activation and expansion via facilitating anabolic 
metabolism.113 Recent studies found that mTORC1 plays a complicated role in T-cell 
maturation.114, 115 In nervous system development, the loss of mTORC1 or mTORC2 
leads to smaller neuron and early death. Conversely, the hyperactivation of mTORC1 
signalling in the brain is associated with various brain disorders.116 
1.7.4 Oncogenic functions of mTOR signalling  
mTOR is widely involved in tumorigenesis of multiple diseases including breast cancer, 
head and neck cancer, colorectal cancer, intestinal cancer, prostate cancer, pancreatic 
cancer and so on.117-122 Sustained mTORC1 signalling in tumours can be achieved in 
different ways. As the downstream of PI3K/Akt and MAPK pathways, which are 
frequently mutated in cancers, mTORC1 is activated subsequently.123 Besides, the 
mutated p53 negatively regulates the lysosomal TSC2, which leads to the hyperactive 
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mTORC1.124 Furthermore, mTOR itself is found to be mutated in a variety of cancers, 
leading to the hyperactivation of mTORC1.125 Sustained mTORC1 signalling promotes 
cell growth and proliferation and accelerates cancer development. mTORC2 is also 
required in prostate cancer in the mouse model and essential for human prostate 
epithelial cells to develop tumours.126 Researchers have also shown that specific 
mTORC2 inhibitor blocks breast cancer cell growth and survival in vivo and in vitro.127 
Also, the loss of mTORC2 signalling inhibits PDAC tumour growth in mouse 
models.128  
1.7.5 mTOR inhibitor 
Rapamycin is the typical inhibitor of mTORC1. It binds the peptidyl-prolyl-isomerase 
FKBP12 to inhibit mTORC1 activation.129 mTORC2 is not sensitive to acute rapamycin 
treatment, but its inhibition can be achieved by the prolonged Rapamycin treatment, 
potentially due to an impaired mTORC2 assembly disturbed by the rapamycin-FKBP12 
complex.130   
 
Previously, a number of rapamycin analogues, namely rapalogs, have been tested by 
clinical trials.131-134 Unfortunately, none of them were as successful as expected from 
pre-clinical research.135 It was found that mTORC2 is activated due to negative 
feedback on insulin/PI3K/Akt signalling when mTORC1 is inhibited alone.97 This 
explanation is proved by increased Akt signalling detected in tumour biopsies from the 
clinical trial.136 It was also reported that the rapalogs only partially inhibited the 
downstream activity of mTORC1, for example, the phosphorylation of S6 was indeed 
inhibited whereas the 4EBP1 activity was resistant in a majority of clinical settings.137, 
138 Moreover, the mTORC1 inhibition promotes the autophagy and micropinocytosis 
which again support cancer growth and survival.139 Therefore, the combination of 
rapalogs and autophagy inhibitors is being tested in clinical trials. The preliminary 
results in melanoma patients showed an improved efficacy compared with the rapalog 
monotherapy.140 
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Recently, inhibitors targeting both mTORC1 and mTORC2 are developed and tested in 
clinical trials. These novel inhibitors are ATP-competitive catalytic inhibitors against 
mTOR, which suppress both mTORC1 and mTORC2 catalytic activity directly. 
Although these new mTOR inhibitor were more effective than rapalogs in preclinical 
research, the feedback activation of PI3K also took place after the long-term treatment 
with ATP-competitive mTOR inhibitors.141 Thus, the dual PI3K/mTOR inhibitors are 
currently under development to overcome this feedback activation.  
 
 
1.8 Arp2/3 complex 
1.8.1 Physiological function of Arp2/3 complex 
The actin-related protein 2/3 (Arp2/3) complex is composed of seven subunits, two of 
which are Arp2 and Arp3, actin-related proteins, the other five of which are Arpc1 to 5. 
Arpc1 can be encoded by paralogous genes Arpc1a and Arpc1b, Arpc5 also has two 
isoforms: Arpc5 and Arpc5l.142 In the inactive conformation of Arp2/3 complex, Arp2 
and Arp3 are separated,143 when it is activated, Arp2/3 complex binds to the pre-existing 
actin filaments, also called mother filaments, Arp2 and Arp3 move close and form a 
dimmer on the sides of mother filaments, promoting a new filament (daughter filament) 
nucleation on the dimmer.144 Therefore, the Arp2/3 complex function as generating 
branched actin networks. Its activity is mainly regulated by nucleation-promoting 
factors (NPFs) such as N-WASP or WAVE.145, 146 Different paralogous subunits in 
Arp2/3 complex also show different activity in promoting actin polymerization, Arpc1b 
and Arpc5l are more efficient.142 Besides, the phosphorylation of Arp2 is also essential 
for the activity of the Arp2/3 complex.147 Small molecules CK-666 and CK-869 are 
commonly used inhibitors specifically for Arp2/3 complex. CK-666 binds between 
Arp2 and Arp3, stabilizing Arp2/3 inactive conformation. CK-869 has a different 
binding site on Arp3, which reduces the stability of Arp2-Arp3 dimmer and inhibits 
Arp2/3 activation.143   
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1.8.2 Oncognic function of Arp2/3 complex 
Arp2/3 subunits were studied in different diseases in past decades. In PDAC cell lines, 
Arpc1a gene is overexpressed, the silencing of Arpc1a in AsPC-1 cell line suppresses 
cell migration and invasion.148 Besides, Arpc3 and Arpc4 are also overexpressed, 
especially the silencing of Arpc4 inhibits cell migration in all tested PDAC cell lines.149 
In colorectal cancer, the expression of Arp2 and its regulator WAVE2 is positively 
correlated with the liver metastasis.150 Similarly, the co-expression of Arp2 and WAVE2 
in lung adenocarcinoma and breast ductal carcinoma predicts shorter survival time.151, 
152   
 
 







Previously, we and others have provided genetic evidence defining the oncogenic 
function of both mTORC1 and mTORC2 in overt PDAC.128, 153-156 However, it remains 
unknown whether these two mTOR complexes are involved early pancreatic 
carcinogenesis, especially in ADM and PanIN formation. To address this, a well-
established mouse model of inflammation-accelerated KrasG12D-driven early pancreatic 
carcinogenesis was used. 
 




3. Material and Methods                                                                                   
 
 
3.1 Instruments and chemicals 
3.1.1 Instruments 
 
Analytic Balance Sartorius, Goettingen, Germany 
PH meter Peqlab Biotechnologie GmbH, Erlangen, Germany 
Biometra TOne Analytic Jena AG, Jena, Germany 
X-RAY CASSETTE X-ray GmbH, Augsburg, Germany 
Microtome RM2255 Leica, Wetzlar, Germany 
GLOMA multi detection system Promega, Madison, USA 
Nanodrop 2000 Thermo Fisher Scientific, Waltham, USA 
HERA safe Thermo Scientific, Langenselbold, Germany 
HERA cell 150 Thermo Scientific, Langenselbold, Germany 
Axiovert 40 CFL Zeiss, Oberkochen, USA 
Electrophoresis chamber Bio-Rad, Carlifonia, USA 
Vortex mixer   Neolab, Heiderburg, Germany 
TissueLyser QIAGEN, Hilden, Germany 
Centrifuge 5415 R Eppendorf, Hamburg, Germany 
Centrifuge 5424 Eppendorf, Hamburg, Germany 
Titromax 100 Heidolph Instruments GmbH, Schwabach, Germany 
Multifuge 3SR+ Thermo Fisher Scientific, Waltham, USA 
Roller mixer Merck, Darmstadt, Germany 
Cryostat CM 3000 Leica Microsystems, Bensheim, Germany 
 
3.1.3 Miscellaneous 
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Hypodermic-needle Braun, Melsungen, Germany 
PAP Pen Kisker, Steinfurt, Germany 
Star Seal Advanced Polyolefin Film Starlab, Hamburg, Germany 
SafeSeal micro tube SARSTEDT, Nuembrecht, Germany 
Cell strainer 100 μm Corning Incorporated, New York, USA 
RT-PCR primers Merck, Darmstadt, Germany 
Vasofix Safety BRAUN, Melsungen, Germany 
Weighing tray Carl Roth GmbH+Co.KG, Karlsruhe, Germany 
Disposable Pasteur pipettes Carl Roth GmbH+Co.KG, Karlsruhe, Germany 
Feather disposable scalpel Daigger Scientific, Vernon Hills, USA 
Medical examination gloves Critical Environment Solutions Ltd, Swindon, England 
Pipetboy INTEGRA Biosciences GmbH, Biebertal, Germany 
Multiply-uStrip 0.2 ml chain SARSTEDT AG, Nuembrecht, Germany 
8-Lid chain, flat SARSTEDT AG, Nuembrecht, Germany 
96-well PCR microplate STARLAB, Hamburg, Germany 
Filter Tip STARLAB, Hamburg, Germany 
Embedding cassettes Carl Roth, Karlsruhe, Germany 
Vacuum Filter Sarstedt, Newton, USA 
12-well cell culture plate Merck, Darmstadt, Germany 
Cell culture dishes, 60*15mm Merck, Darmstadt, Germany 
Disposable forceps Megro GmbH, Wesel, Germany 
Syringe 1ml and 5ml BRAUN, Melsungen, Germany 
Serological pipette 5ml-50ml Merck, Darmstadt, Germany 
Syringe Filter 0.2 μm Thermo Scientific, Waltham, USA 
Cell strainer 100 μm Corning Incorporated, New York, USA 
Medical X-ray film Agfa HealthCare, NV, Mortsel, Belgium 
Nitrocellulose blotting membrane GE Healthcare, Germany 
Parafilm Merck, Darmstadt, Germany 
Tube 15 ml and 50 ml Merck, Darmstadt, Germany 
Insulin syringe BRAUN, Melsungen, Germany 
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Micro tube Sarstedt, Nuembrecht, Germany 
 
3.1.2 Chemicals and reagents 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
BCA Protein Assay Kit Thermo Fisher Scientific, Waltham, USA 
Tamoxifen Merck, Darmstadt, Germany 
Phosphatase inhibitor cocktail tablet Roche, Mannheim, Germany 
Protease inhibitor cocktail tablet Roche, Mannheim, Germany 
Western Blotting detection reagents GE Healthcare, Buckinghamshire, UK 
SignalStain Ab Diluent Cell signaling, Frankfurt, Germany 
Sample reducing agent (10x) Invitrogen, Carlsbad, USA 
LDS sample buffer (4x) Invitrogen, Carlsbad, USA 
Ethonal absolut Otto Fischar GmbH, Saarbrucken, Germany 
Roticlear ROTH, Karlsruhe, Germany 
Aqua BRAUN, Melsungen, Germany 
Isofluran CP-Pharma Handelsgesellschaft mbH, Burgdorf, 
Germany 
Saline Fresenius Kabi Deutschland GmbH, Homburg, 
Germany 
Powdered milk Carl Roth GmbH+Co.KG, Karlsruhe, Germany 
Agarose VWR, Radnor, USA 
Bovines Serum Albumin Roche Diagnostics, Mannheim, Germany 
DMSO Roche Diagnostics, Mannheim, Germany 
30% Acrylamide Carl Roth GmbH, Karlsruhe, Germany 
TEMED Carl Roth GmbH, Karlsruhe, Germany 
Eosin Merck, Darmstadt, Germany 
Hamotoxylin Roche Diagnostics, Mannheim, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Chloroform Merck, Darmstadt, Germany 
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Citrate Merck, Darmstadt, Germany 
DMEM-medium Merck, Darmstadt, Germany 
FSC Merck, Darmstadt, Germany 
Dulbecco’s PBS (1×) Merck, Darmstadt, Germany 
Trypsine/EDTA (10×) Merck, Darmstadt, Germany 
Penicillin/Streptomycin (1×)   Merck, Darmstadt, Germany 
PBS powder Merck, Darmstadt, Germany 
Protein ladder Thermo Fisher Scientific, Waltham, USA 
Collagen Type I Corning Incorporated, New York, USA 
Hanks’ salt solution Biochrom GmbH, Berlin, Germany 
Waymouth’s MB 752/1 Medium (1×) Gibco, Waltham, USA 
Collagenase P Roche, Mannheim, Germany 
Soybean trypsin inhibitor Gibco, Waltham, USA 
HEPES Gibco, Waltham, USA 
Caerulein Merck, Darmstadt, Germany  
 
 
3.2 Patient material and tissue collection 
 
PDAC and chronic pancreatitis tissues were obtained from patients who carried out 
pancreatic resections. All the diagnoses were histologically confirmed. Samples were 
either partially snap-frozen in liquid nitrogen or partially fixed in paraformaldehyde 
(PFA) solution for 24 hours and then embedded in paraffin for histological analysis. 
Normal pancreas tissues were obtained through an organ donor program from 
previously healthy donors; all the samples had previously been collected at Technical 
University Munich and written informed consent had been obtained from these patients. 
The use of pancreatic tissues for this study was approved by the local Ethics committee 
(approval number: 80/17s). 
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3.3 Experimental procedures 
3.3.1 Animals 
Mice line harbouring floxed allele of Rptorloxp/loxp(Rptorfl/fl, stock number: 013188), 
Rictorloxp/loxp (Rictorfl/fl, stock number: 020649), the pancreas-specific inducible Cre 
recombinase line Ptf1aCreERTM (also known as p48CreERTM, stock number: 019378) and 
LSL-Rosa26CAG-tdTomato (stock number: 007914) were purchased from The Jackson 
Laboratory (Bar Harbor, Maine, USA). Ptf1aCre/+ (also known as p48Cre/+) mice and 
LSL-KrasG12D mice have been described previously.153 The wild type C57BL/6J mice 
were obtained from Charles River Laboratory (Sulzfeld, Germany). The Arpc4flox/flox 
line was generated by R.K. and M.I. as previously described.157 
3.3.2 Animal breeding 
All mice were housed at pathogen-free mouse facility with normal housing conditions 
under a 6 am-6 pm hour light cycle at the Technical University of Munich. Mouse 
husbandry and breeding were maintained for the complete duration of the research. All 
mouse experiments described here were approved by the Technical University of 
Munich and the Institutional Animal Care and Use Committees (Proposal number: 
ROB-55.2-2532.Vet_02-17-83). All experimental procedures were in compliance with 
the German Federal Animal Protection Laws. 
3.3.3 Tamoxifen (TAM) induction 
Tamoxifen suspension was prepared according to the following procedure: 
1. Weigh 80 mg tamoxifen powder in 2 ml micro tube. 
2. Add 200 μl pure ethanol to the micro tube. 
3. Add 1800 μl oil to the micro tube to gain a final concentration of 40 mg/ml, 
shake it up and down for several times. 
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4. Oscillate the micro tube for 5 min at room temperature until tamoxifen powder 
is completely dissolved. 
5. Centrifuge the tube shortly to get rid of the air bubbles inside.  
6. Seal the tube with parafilm and store at -20°C for no longer than 4 months. 
 
Induction procedure: 
1. Warm the stored tamoxifen solution to room temperature. Once thawed, store at 
4°C no longer than one week. 
2. Fill 1 ml syringe with 600 μl tamoxifen working solution, connect it to Vasofix 
Safety tube and fill up the tube with a working solution. 
3. Fix the mouse from the back with one hand, and softly insert the Vasofix Safety 
tube into the stomach with the other hand, administer 100 μl tamoxifen solution 
slowly. 
4. Label the mouse card with date and treatments.  
5. Each mouse was treated with tamoxifen three times per week at the age of 5-6 
weeks (Day1, Day3, Day5). Treatment had to be stopped once mice showed 
apparent adverse effects. 
3.3.4 Caerulein-induced acute pancreatitis  
Acute pancreatitis was induced at 8-9 weeks of age by consecutive caerulein injections 
for two days. All mice were treated with eight hourly intraperitoneal (i.p.) caerulein 
injections (2 μg per mouse each dose).63 Control mice were treated with saline. The 
time point and the day of the last dose were considered as hour 0 and day 0, respectively.   
 
 
3.4 Genotype identification 
3.4.1 Tissue collection for genotyping of transgenic mouse  
Earmarking is carried out using a ear tag puncher to with a consecutive number. The 
Material and Methods                                                 28                                                                                                                                                                                                                                                 
marking scheme is demonstrated in Figure 3. Gather all the ear punch tissue samples in 




Figure 3. Earmarking system of transgenic mouse models 
3.4.2 DNA isolation 
Add 150 μl STE buffer and 5 μl proteinase K to each micro tube containing ear tissue 
sample, cap the tube tightly and shake at 55°C overnight to lyse the tissue. Centrifuge 
at 12000 rpm at room temperature for 10 min. Transfer the supernatant to a new micro 
tube. Add 400 μl 100% Isopropanol to each sample and mix by pipetting. Incubate at 
room temperature for 10 min to precipitate gDNA. Centrifuge at 12000 rpm at room 
temperature for 10 minutes. Discard the supernatant, wash the gDNA pellet with 500 
μl 70% ethanol 2 times. Remove the supernatant and incubate at 37°C for 10 minutes. 




1 L STE buffer 
Dissolve 5.84 g NaCl, 1.21 g Tris, 0.29 g EDTA in 900 ml ddH2O, adjust the pH to 8.0, 
fill up with ddH2O to 1 liter, store at room temperature. 
3.4.3 Polymerase chain reaction (PCR) 
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1. Prepare the following mixture on ice. The primer sequences are displayed in Table 
1. 
 
Components Volume per sample (μl) 
Master mix 12.5 
Primer mixture (forward and reverse) 1 
H2O 10.5 
 
Table 1. Genotyping Primer list for mouse strains 
 
Mouse Strain Primer Type Sequence 5' - 3' 
p48Cre-ERTM 
Forward GAA GGC ATT TGT GTA GGG TCA 
Reverse GGC TGA GTG AGG GTT GTG AG 
Rptorfl/fl 
Forward CTC AGT AGT GGT ATG TGC TCA G 
Reverse GGG TAC AGT ATG TCA GCA CAG 
Rictorfl/fl 
Forward CAA GCA TCA TGC AGC TCT TC 




TGT CTT TCC CCA GCA CAG T 
Common CTG CAT AGT ACG CTA TAC CCT GT 





AAG GGA GCT GCA GTG GAG TA 
Wild type 
Reverse 
CCG AAA ATC TGT GGG AAG TC 
Mutant Forward CTG TTC CTG TAC GGC ATG G 




GGT TCT TGC GAA CCT CAT CA 
Common GAG CAG CCC ATT CGT CCT 
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Wild type 
Reverse 
GTC GCG GTA GCA GTA TTC GT 
Arpc4fl/fl 
Forward AAG CCT TGC CCG AGA TAA TG 
Reverse AAG CAA AGC CAG TCC CTC AC 
 
2. Vortex the mixture shortly and transfer to PCR tube on ice. 
3. Add 1 μl DNA solution into PCR tube from last step. Positive and negative control 
are necessary. 
4. Put tubes in PCR machine under certain thermal conditions as follows: 
 
Temperature (℃) Duration Repetition 
95 10 min 1× 
95 15 sec  
30 
 
55 30 sec 
72 40 sec 
72 5 min 1× 
4 -∞ 1× 
 
3.4.4 Agarose gel electrophoresis 
1. Add 3 g agarose powder into 200 μl TBE buffer, microwave at 600 W for 10 min 
until agarose totally dissolve.  
2. Cool down briefly, add 5 μl ethidium bromide in and shake well.  
3. Cast agarose gel in the mold. Cool down at room temperature until the gel gets 
solidified. 
4. Load 10 μl reaction outcome into well. 
5. Run the gel at 150 volts for 30 min in TBE buffer. TBE buffer must cover the gel. 
6. Image under UV and save image for record. 
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3.5 Three-dimensional (3D) culture 
3.5.1 3D and 2D culture medium preparation 
1. Add all the components together and wait until Soybean Trypsin Inhibitor and 
NaHCO3 totally dissolved, sterilize 3D culture medium with disposable vacuum filter. 
Store at 4°C for up to 2 months. 
2. 3D culture medium was mainly used for 3D collagen gel preparation, 2D culture 
medium was mainly for acinar cell cluster culture. 
3. 3D culture medium composition for total volume of 200 ml is as follows: 
 
Components Volume/Amount Concentration 
Waymouth's MB 752/1 media 154 ml - 
FBS 40 ml 20% 
Penicillin/streptomycin 4 ml 2% 
Soybean Trypsin Inhibitor 40 mg 0.2 mg/ml 
5000× Dexamethasone 40μl 4 μg/ml 
HEPES 2 ml 10 mM 
NaHCO3 0.52 g 2.6 mg/ml 
 
4. 2D culture medium composition for total volume of 200 ml is as follows: 
 
Components Volume/Amount Concentration 
Waymouth's MB 752/1 media 177 ml - 
FBS 20 ml 10% 
Penicillin/streptomycin 2 ml 1% 
Soybean Trypsin Inhibitor 20 mg 0.1 mg/ml 
5000× Dexamethasone 20 μl 2 μg/ml 
HEPES 1 ml 5 mM 
NaHCO3 0.26 g 1.3 mg/ml 
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Recipe 
5000× Dexamethasone 
Dissolve 20 mg dexamethasone powder in Waymouth's MB 752/1 media, fill up to 1 
ml to generate a 20 mg/ml stock. Aliquot and store at -20°C. 
3.5.2 Acinar cell isolation 
Pancreas dissection and harvest (Day -1) 
A rapid organ harvest is crucial for sufficient extraction of viable acinar cells.  
1. Euthanize mouse with isoflurane. 
2. Fix the mouse supinely on the dissection plate. Sterilize mouse abdomen with 
70% ethanol spray. Median laparotomy with sterile scissors and forceps to 
expose the whole abdominal cavity. 
3. Grab and pull the spleen with forceps to expose the mesentery between stomach 
and pancreas and cut it with scissors to dissect the pancreas from stomach.  
4. Pull the spleen vertically, liberate the head of pancreas from the beginning of 
small intestine with scissors carefully and rapidly and resect the lifted pancreas.  
5. Hold the spleen with forceps and dissect the pancreas. 
6. Transfer the pancreas to chilled 5% FBS/Hank’s solution on ice immediately. 




5% FBS/Hanks’ solution 
Add 25 ml FBS to 475 ml Hanks’ balanced salt solution, store at 4℃. 
4% Formalin 
Mix the same amount of 8% formalin stock and ddH2O to get 4% formalin, store at 
room temperature. 
 
Enzymatic digestion of pancreas (Day -1) 
From this step, the rest procedures were performed with sterile dissection tools in a 
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hood with laminar flow. 
1. Pick the pancreas with sterile disposable plastic forceps from chilled 5% 
FBS/Hanks’ solution and transfer it to a 6 cm culture dish containing 5 ml 
collagenase P solution (1mg/ml, prepared with 5% FBS/Hanks’ solution, 
filtered with 0.2 μm sterile strainer).  
2. Mince the pancreas into 1 mm small pieces and keep the dish in a 37℃ 
incubator for 15 min. 
3. Remove pancreas tissue together with the collagenase P solution to a 50 ml 
sterile Falcon tube with 10 ml 5% FBS/Hanks’ solution and centrifuge at 300 
rpm for 5 min.  
4. Aspirate the supernatant, wash pancreatic tissue with 10 ml 5% FBS/Hanks’ 
solution, swirl the washing solution until tissue cluster disperse and centrifuge 
at 300 rpm for 5min. 
5. Discard the supernatant, re-suspend the pellet in 25 ml 5% FBS/Hanks’ 
solution added in another 5 ml FBS by pipetting gently up and down with 25 
ml pipet. 
6. Transfer the tissue suspension with 25 ml pipet to a new 50 ml Falcon tube 
through a 10 cm sterile mesh. Keep the tip of the pipet on the mesh while 
rotating and pipetting to grind pancreatic tissue into the acinar cell cluster. 
Centrifuge at 300 rpm for 5 min. 
7. Remove the supernatant, wash the pellet with 10 ml 5% FBS/Hanks’ solution 
by swirling to resuspension. Centrifuge at the same speed with last step for 5 
min. 
8. Aspirate the supernatant, re-suspend the pellet with 10 ml 2D culture medium 
by pipetting softly up and down.  
9. Dilute 5 μl 20 ug/ml caerulein stock solution in 495 μl 2D culture medium 
evenly, add 100 μl diluent to cell suspension. 
10. Mix acinar cell suspension gently and transfer to a sterile 10 cm culture dish. 
11. Incubate acinar cells in 2 ng/ml caerulein-included 2D culture medium under 
37℃, 5% CO2 condition for 24 hours. 
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Recipe 
Collagenase P solution 
Dissolve 50 mg collagenase P powder in 5% FBS/Hanks’ solution, fill up to 50 ml to 
generate 1 mg/ml collagenase P solution, sterilize with 0.2 μm filter, store at 4°C less 
than 2 weeks. 
Caerulein stock solution 
Dissolve 2 mg caerulein powder in sterile saline, fill up to 100 ml to get 20 μg/ml 
concentration, sterilize by passing through 0.2 μm filter, aliquot in 2 ml or 1.5 ml sterile 
micro tube, store at -80°C.  
3.5.3 Collagen gel preparation and 12-well plates coating (Day 0) 






Final Volume for One Well in 12-Well 
Plate 
First Layer 1.5 mg/ml 1.5 ml 
Second Layer 1.0 mg/ml 0.5 ml 
 
Components of Collagen 
Gel 
Volume (V) 
10× PBS VPBS =10% VFinal Volume 
Collagen 
VCollagen = VFinal Volume * ConFinal Collagen Concentration 
 / ConOriginal Collagen Concentration 
NaOH (1 M) VNaOH = VCollagen * 0.023 
3D Culture Medium V3D culture medium = VFinal Volume - VCollagen - VPBS - VNaOH 
NaHCO3 (7.5%) VNaHCO3 = VFinal Volume / 60 
V: volume; Con: concentration 
 
2. Pipet 500 μl mixture to each well of 12-well plate as the following diagram shows, 
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Figure 4. 3D culture diagram for each well in 12-well plate. 
 
3. Leave the plate at 37℃ for 30 min until collagen mixture gets solidified when it is 
ready to seed the first layer.  
4. The original concentration of collagen product is variable. It changes with Lot. 




Volume for One Well in 12-Well Plate 
Volume for First Layer (μl) 
Volume for Second 
Layer (μl) 
10× PBS 150 50 
Collagen (4 g/ml) 562.5 187.5 








Dissolve 4.775g PBS powder in sterile ddH2O, fill up to 50 ml. 
Sterilize with 0.2 μm filter, aliquot in 1.5 ml micro tube and store at 4°C 
1 M NaOH 
Dissolve 2 g NaOH in sterile ddH2O, fill up to 50 ml. 
Sterilize with 0.2 μm filter, aliquot in 1.5 ml micro tube and store at 4°C 
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7.5% NaHCO3 
Dissolve 3.75 g NaHCO3 in sterile ddH2O, fill up to 50 ml. 
Sterilize with 0.2 μm filter, aliquot in 1.5 ml micro tube and store at 4°C 
3.5.4 Seeding of acinar cell in collagen gel (Day 0) 
1. Prepare collagen gel for the first layer on ice following the above description. 
2. Transfer acinar cell suspension to a new 50 ml Falcon tube, centrifuge at 300 
rpm for 5 minutes. Discard the supernatant, wash acinar cell pellet with the same 
protocol mentioned above. 
3. Re-suspend acinar cell clusters with collagen gel, pipet up and down gently with 
1 ml tip for short time, seed 1.5 ml mixture in each collagen-coated well. 
4. Leave 12-well plates at 37℃, 5% CO2 for 60 min until the solidification of 
collagen-cell mixture.  
5. Add 2 ml 2D culture medium with substances into each well and incubate at 
37℃, 5% CO2 condition until time point. The substances list is in Table 2. 
 











C8273 0.2 µM Sigma-Aldrich 
Rapamycin 553210 100 nM Sigma-Aldrich 
Akt inhibitor 
(Akti 1/2) 





Ab143783 3 µM Abcam 
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hydrochloride 
(BIM XI) 
EHT1864 3872 50 µM 
TOCRIS Bioscience (Wiesbaden-
Nordenstadt, Germany) 
SC79 SML0749 11 µM Sigma-Aldrich 
Cycloheximide 
(CHX) 
46401 178 µM Sigma-Aldrich 
TGF-α 239-A 100 ng/ml 




TGF-α stock solution 
Add 6 μl acetic acid to 10 ml sterile PBS solution to prepare 10 mM acetic acid 
solution, filter with 0.2 μm strainer, pipet 1 ml liquid to 100 μg recombinant human 
TGF-α to reconstitute at 100 μg /ml, aliquot in 1.5 ml micro tube and store at -80°C 
less than 3 months. 
 
 
3.6 RNA isolation from 3D culture (Day 2) 
 
1. Aspirate 2D culture medium from the well, pinch the collagen gel with 
disposable plastic forceps and transfer to 1.5 ml micro tube, centrifuge at 1200 
rpm for 2 minutes. 
2. Discard the supernatant in the micro tube, move the gel pellet to a new 2 ml 
micro tube with a small steel bead inside. 
3. Lyse collagen-cell mixture with 1 ml TRLzol reagent, oscillate at 50 times per 
minute for 5 minutes until the mixture is homogeneous. 
4. Pipet the homogeneous mixture to a new 1.5 ml RNase-free micro tube. Incubate 
5 minutes to dissociate the nucleoproteins complex completely. 
5. Add 200 μl chloroform, then cap the tube tightly, shake with hands strongly for 
15 seconds. 
6. Incubate at room temperature for 2-3 minutes. 
7. Centrifuge at 12,000g at 4°C for 15 minutes. The mixture is separated into 3 
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layers, the upper aqueous phase, the lower organic phase and interphase. 
8. The rest procedure was performed with RNeasy mini kit (Qiagen, Venlo, 
Netherlands), according to the manufacturer’s procedures.   
 
 
3.7 Reverse transcription 
 
The RNA samples from 3D culture were processed for first strand cDNA synthesis with 
reverse transcriptase. The concentration of RNA samples was measured by Nanodrop 
2000, the following procedure is done by RevertAid H Minus First Strand cDNA 
Synthesis Kit (Thermoscientific, Germany). Add 0.1-1 μg total RNA and 1 μl 
oligo(dT)18 primer to a sterile, nuclease-free tube on ice, fill up with nuclease-free water 
to 12 μl. Then add 4 μl 5× Reaction Buffer, 1 μl RiboLock RNase Inhibitor, 2 μl 10 mM 
dNTP Mix, 1 μl Reverse Transcriptase to the above tube. Mix gently and centrifuge. 
Incubate for 60 min at 42℃.Terminate the reaction by heating at 70℃ for 5 min. Dilute 




3.8 Quantitative real-time polymerase chain reaction (QRT-PCR) 
  
5 μl of diluted cDNA samples were mixed with 10 μl SYBR green master mix, 1 μl 
forward primer, 1 μl reverse primer and 3 μl ddH2O. QRT-PCR was performed using 
the LightCycler480. cDNA samples were incubated at 95℃ for 5 min to denature, then 
amplified for 45 cycles, each composed of incubation at 95℃ for 15 seconds and at 60℃ 
for 45 seconds. The mRNA expression level of the target gene was normalized by the 
mouse housekeeping gene Rps29 (ribosomal protein S29) using the LightCyclerTM480 
software.153 The primer sequences are showing in Table 3. 
 
Table 3. Sequences of primers used for QRT-PCR analysis of mouse genes 
 
Gene Name Sense (5’→3’) Antisense (5’→3’) 









































3.9 Paraformaldehyde (PFA) fixation of 3D culture (Day 2) 
 
1. Discard culture medium from the well, pinch the collagen gel from two ends of 
the diameter gently with disposable plastic forceps and lie it in cassette rapidly. 
2. Put the cassette into 4% PFA solution and incubate at room temperature 
overnight. 
3. Transfer the cassette to PBS, after washing, go through dehydration machine. 




3.10 Protein isolation from 3D culture and frozen tissue 
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Proteins were extracted from 3D culture with 1 x RIPA buffer containing phosphatase 
and protease inhibitors. Transfer collagen gel to 1.5 ml tube with forceps, centrifuge at 
12,000g for 2 minutes. Remove the supernatant and wash the collagen pellet with PBS 
for 2 times. From this step forward, the protein isolation from 3D culture and frozen 
tissue were performed using the same experimental procedures. Oscillate the pellet 
strongly at 50 times per minute for 5 minutes with steel beads in 100 μl RIPA buffer. 
Incubate protein samples on ice for 40 min to get complete homogenized. The samples 
were then centrifuged at full speed at 4℃ for 20 minutes. Transfer the supernatant 
(protein lysate) to a new tube on ice. Measure protein concentration using the BCA kit.  
 
Recipe 
1× RIPA buffer 
Dilute 1 ml 10× RIPA stock solution in 9 ml ddH2O, dissolve one tablet of phosphatase 




3.11 Western-blot analysis 
 
After measurement of protein concentration, denature the same amount of protein and 
run polyacrylamide gel to separate it, and then transfer to a nitrocellulose (NC) 
membrane. 5% milk incubation for 1 hour at room temperature was used to block 
unspecific binding on the membrane. Then transfer the membrane to the primary 
antibody in blocking buffer for overnight incubation at 4°C. The concentration of 
primary antibody and secondary antibody is displayed in Table 4 and 5. After washing, 
incubate the membrane with secondary antibody in 5% milk for 1 hour at room 
temperature. Wash the membrane and add on detection solution evenly. Develop the 
image on x-ray film in the darkroom by means of chemiluminescence technique. 
 
Recipe 
10× Running buffer 
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Dissolve 30.0 g of Tris base, 144.0 g of glycine in dH2O, fill up to 1000 ml. Store at 
room temperature and dilute to 1× before use. 
1× Running buffer 
Dilute 100 ml 10× running buffer to 900 ml dH2O, add 10 ml 10% SDS to the mixture. 
1× Blotting buffer 
Mix 200 ml methanol with 100 ml 10x running buffer, add 700ml dH2O to 1 L. 
 














2280 WB Cell Signaling Technology 
Rabbit Anti-Rptor pAb# 20984-1-AP IHC Proteintech 
Rabbit Anti-Rictor 
mAb# 
2140 WB Cell Signaling Technology 
Rabbit Anti-p-
mTORS2448 mAb# 
5536 WB Cell Signaling Technology 
Rabbit Anti-p-
mTORS2448 mAb# 
2976 IHC Cell Signaling Technology 
Rabbit Anti-p-AktS473 
mAb# 
4060 WB, IHC Cell Signaling Technology 
Rabbit Anti-p-AktT308 
mAb# 
4056 WB Cell Signaling Technology 
Rabbit Anti-Akt mAb# 9272 WB Cell Signaling Technology 
Rabbit Anti-p-S6S235/236 4858 WB, IHC Cell Signaling Technology 
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mAb# 
Rabbit Anti-t-S6 mAb# 2217 WB Cell Signaling Technology 
Rabbit Anti-p-Ndrg 
1T346 mAb# 
5482 WB, IHC Cell Signaling Technology 
Rabbit Anti-t-Ndrg 1 
mAb# 
9408 WB Cell Signaling Technology 
Phospho-Myosin Light 
Chain 2 (Ser19) Mouse 
mAb# 
3675  IF Cell Signaling Technology 
Mouse Anti-Rac1 
mAb# 
8815 WB Cell Signaling Technology 
Goat Anti-Arpc4 Ab# EB08249 WB Everest Biotech Ltd 
Rabbit Anti-Arpc1b 
pAb# 
AP4321 WB ECM Biosciences 
Rabbit Anti-Arp2 pAb# AP3861 WB, IHC ECM Biosciences 
Rabbit Anti-Arp3 pAb# AP4581 WB, IHC ECM Biosciences 
Rabbit Anti-α-Amylase 
mAb# 
3796 IHC, IF Cell Signaling Technology 
Rat Anti-Krt19 mAb# AB_2133570 IHC, IF 
Developmental Studies 
Hybridoma Bank 
Rabbit Anti-Claudin 18 
mAb# 
700178 IHC Invitrogen 
Rabbit Anti-Glucagon 
mAb# 
2760 IHC Cell Signaling Technology 
Rabbit Anti-Insulin 
mAb# 
4590 IHC Cell Signaling Technology 
Mouse Anti-Muc5AC 
mAb# 
MA5-12178 IHC Invitrogen 
Mouse Anti-F-actin Ab205 IF Abcam 




4877 WB Cell Signaling Technology 
Mouse Anti-β-actin Ab# SC-1615 WB Santa Cruz Biotechnology 
Mouse Anti-GAPDH 
mAb# 




9375 WB Cell Signaling Technology 
Rabbit Anti-PKCα 
mAb# 
2056 WB Cell Signaling Technology 
 
WB = western blot; IHC = Immunohistochemistry; IF = Immunofluorescence; Ab# = 
antibody 
 






Rabbit HRP (horseradish 
peroxidase)-labelled Anti-Rat 
IgG Ab#  




Goat HRP-Labelled Polymer 
Anti-Mouse Ab# 




Goat HRP-Labelled Polymer 
Anti-Rabbit Ab# 




Simple StainTM MAX PO  414141F IHC 
Nichirei 
Bioscience 
Simple Stain Mouse MAX PO  414341F IHC 
Nichirei 
Bioscience 
Goat Alexa Fluor 488 Anti-
Mouse IgG Ab# 
115-546-062 IF  Dianova  
Goat Alexa Fluor 594 Anti-Rat A-11007  IF  Invitrogen  
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IgG Ab# 
Goat Alexa Fluor 594 Anti-
Rabbit IgG Ab# 
A-11034 IF Invitrogen 
Goat Alexa Fluor 488 Anti-
Rabbit IgG Ab# 
A-11012 IF Invitrogen 
Goat Alexa Fluor 488 Anti-Rat 
IgG Ab# 
A-11006 IF Invitrogen 
Goat Alexa Fluor 594 Anti-
Mouse IgG Ab# 
A-11005 IF Invitrogen  
Anti-Mouse IgG HRP Conjugate W4028 WB 
PROMEGA, 
Madison, USA 
Anti-Rabbit IgG HRP Conjugate W4018 WB 
PROMEGA, 
Madison, USA 










3.12 Active Rac1 pull-down assay 
 
GTP-bound Rac1 was detected in whole pancreas tissue lysate or acinar explants using 
a commercially available kit (Active Rac1 Detection Kit, #8815, Cell Signaling 
Technology, NEB, Frankfurt/Main, Germany) according to the manufacturer’s 




3.13 Immunohistochemistry (IHC) and immunofluorescence (IF) 
 
Obtained organ were preserved in 4% PFA overnight, then embedded in paraffin and 
cut into slices with 2 μm thickness. Sections were subjected to Hematoxylin and eosin 
(H&E), IHC and IF staining. Generally, citrate buffer was used for heat-induced epitope 
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retrieval. Briefly, IHC and IF staining was performed with 10% goat serum in PBST as 
blocking. Primary antibody was diluted in antibody dilution and incubate at 4℃ 
overnight. The respective secondary antibody was added on the slice and incubate at 
room temperature for 1 hour. The primary and secondary antibody is displayed in Table 
3 and 4. After washing, for IHC staining, DAB diluent was used to display the positive 
staining, for IF, DAPI was add on the slice before mounting. For quantification of IHC 
staining, sections were scanned by microscope under 5× magnification. The analysis 




Dissolve 2.94 g Citrate powder in dH2O, adjust the pH to 6, fill with water up to 1L. 
Store at room temperature less than 2 weeks.  
10% Goat serum 
Dilute 100 μl goat serum in 900 μl PBST before using, keep it on ice. 
 
 
3.14 Mass spectrometry-based proteomics 
 
For mass spectrometry, the protein was isolated with urea lysis buffer. After measuring 
protein concentration with BCA kit, Coomassie stain was performed to show proteins 
on the polyacrylamide gel before sending for protein mass spectrometry analysis 
(Figure 5). It was done in cooperation with Dr. Christina Ludwig by HF-KMS01 
(Thermo Fisher Scientific, USA) instrument in Bavarian Center for Biomolecular Mass 
Spectrometry of Technical University of Munich. 
 
Recipe 
8 M Urea lysis buffer 
Dissolve 2.4 g urea, 9.3 mg EDTA, 39.53 mg NH4HCO3, 5 μl 1M DTT stock solution 
and half tablet of protease inhibitor cocktail in H2O, fill up to 5 ml. Store at room 
temperature, always prepares fresh buffer before use. 
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Figure 5. Coomassie stain of protein samples used for mass spectrometry analysis. 
 
 
3.15 Downstream differential abundance analysis 
 
The quantitative proteomic results were further statistically analysed using the Perseus 
software (Version: 1.6.10.43, http://www.coxdocs.org/doku.php?id=perseus:start),158 
to obtain mTORC1 and mTORC2 proteomic signatures and related KEGG pathways 
using the default setting. In brief, LFQ intensities were transformed by Log2(x) and the 
missing values were imputed and replaced according to the normal distribution. For the 
generation heatmap, a multiple-sample test was applied to KrasG12D, KrasG12D; Rptor-/- 
and KrasG12D; Rictor-/- samples to yield differentially expressed proteins using ANOVA 
test followed by Permutation-based p-value correction (cut-off FDR: 0.05). To obtain 
mTORC1- or mTORC2-specific proteomic signature, a two-sample test (Student’s T-
test) was applied and p-value is followed by Permutation-based correction (cut-off FDR: 
0.01, fold change S0=0.1) to generate a list of differentially expressed proteins between 
KrasG12D and KrasG12D; Rptor-/- samples as well as between KrasG12D and KrasG12D; 
Rictor-/- samples (Figure 25). The list of upregulated proteins (KrasG12D vs. KrasG12D; 
Rptor-/- and KrasG12D vs. KrasG12D; Rictor-/-) was considered as specific proteomic 
signatures (Figure 26) and they were subjected to KEGG pathway enrichment analysis. 
As such, p values were calculated by Fisher exact test and followed by Benjamini-
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3.16 Quantification of ADM and PanIN 
 
For ADM quantification in 3D culture, 5 pictures were taken from one well of each 
mouse on day2. The area of ADM was calculated by ImageJ (Maryland, USA). For 
PanIN and α-Amylase percentage quantification in vivo, the whole slide of relative IHC 
staining was scanned, the area calculation was done by ImageJ, the number of lesions 
was calculated manually. 
 
 
3.17 Statistical analysis 
 
GraphPad Prism V.5 Software (GraphPad, San Diego, California, USA) was used for 
the statistical analysis. All experiments were repeated for three times. An unpaired 
Student’s t-test was used to evaluate the difference between the two groups. P <0.05 was 
considered as statistical significance standard. Results are expressed as mean ± SD.  







4.1 mTOR signalling is activated in ADM in vivo 
 
Firstly, we stained histological sections of normal pancreas (n=5), chronic pancreatitis 
(CP) (n=10) and PDAC (n=20) for a number of activation markers for mTORC1 (p-
mTORS2448, RPTOR and p-S6S235/236) and mTORC2 (p-mTORS2448 and p-NDRG1T346) 
signaling. In accordance with previously published data128, 153, we observed that acinar 
cells in normal pancreas were weakly stained, but PDAC cells were in general positive, 
indicating a dual activation of mTORC1 and mTORC2 signalling in established PDAC 
(Figure 6). To our special attention, ADM lesions in CP sections were particularly 
stained for these activation markers of mTORC1 and mTORC2 (Figure 6). To further 
validate this, we compared their expressions in normal pancreas and CP tissues using 
western-blot analysis in humans. Indeed, the expression of activation markers for 
mTORC1 (p-mTORS2448, RPTOR and p-S6S235/236) and mTORC2 (p-mTORS2448, 
RICTOR, p-AKTS473 and p-NDRG1T346) were increased in CP tissues comparing to the 
normal pancreas (Figure 7).  
 
Besides, we tested whether mTORC1 and mTORC2 were also activated in a mouse 
model of early pancreatic carcinogenesis driven by KrasG12D and caerulein-induced 
pancreatitis. Here, we observed that both mTORC1 and mTORC2 were activated in 
these mouse ADM lesions, which is consistent with the findings in human chronic 
pancreatitis (Figure 8). These in vivo data suggest that mTOR signalling is activated in 
precursor lesion of PDAC. 
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Figure 6. Representative IHC pictures show p-mTORS2448, RPTOR, p-S6S235/236 and p-NDRG1T346 in the 




Figure 7. Western-blot analysis demonstrates the expression of p-mTORS2448, RPTOR, RICTOR, p-
S6S235/236 and p-AKTS473 and p-NDRG1T346 in normal (n=4) and chronic pancreatitis (n=6) tissues.   
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Figure 8. Representative IHC pictures show p-mTORS2448, RPTOR, p-S6S235/236 and p-NDRG1T346 in the 
ADM lesions of KrasG12D mouse model; Scale bars: 50 μm. 
 
 
4.2 mTOR signalling is involved in ADM formation in vitro 
 
To clarify if mTOR signalling is involved in ADM in vitro, we performed a ADM 
formation assay in 3D culture system. It was reported that isolated wild-type acinar 
cells treated with TGF-α or acinar clusters with spontaneous oncogenic Kras expression 
were able to differentiate to duct-like structures in the collagen matrix.31 In the current 
study, we further optimized the protocol and stimulated explanted wild-type cells with 
2 ng/ml caerulein for 24 h before implantation into the 3D culture. As such, the isolated 
acinar clusters are able to differentiate to metaplastic ductal lesions even in the absence 
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of TGF-α treatment (Figure 10A). This result was confirmed by QRT-PCR. We isolated 
RNA from TGF-α-mediated and control ADM (PBS treated) at 48h and also from fresh 
wide-type acinar cells, and checked mRNA expression level of α-Amylase, the marker 
of acinar cell; Krt19, the marker of ductal cell; Rbpjl and Mist1, acinar cell identity 
factors; Rbpj and Pdx1, acinar cell dedifferentiation factors.159, 160 The expression of α-
Amylase, Rbpjl, Mist1 reduced dramatically in TGF-α-mediated and control ADM 
compared to fresh acinar cell, also the expression of Krt19, Rbpj, Pdx1 increased 
significantly (Figure 9), which indicated acinar cell dedifferentiation to ductal 
phenotype in 3D culture. However, TGF-α-induced and oncogenic KrasG12D-driven 
ADM are bigger than control ADM in the 3D culture at 48h (Figure 10A). These data 
suggested that TGF-α stimulation and oncogenic Kras promote ADM formation in vitro 
(Figure 10A). On this basis, we checked mTOR, Rptor, Rictor mRNA expression level 
in these ADM. QRT-PCR results showed that both Rptor and Rictor increased 
significantly in TGF-α-induced and KrasG12D-driven ADM compared with control, also 
mTOR was upregulated in TGF-α-mediated ADM compared with control (Figure 10B). 
Also, proteins were isolated from these ADM, and western blot was implied to analyze 
the activation of mTOR signalling. It shows that p-mTORS2448, Rptor and Rictor, 
members of mTOR complexes, are overexpressed in KrasG12D-mediated and TGF-α-
induced ADM compared with control, also, p-PkcαT638, p-Ndrg1T346 and p-S6S235/236, 
the downstream targets of mTOR signalling upregulate significantly; p-AktS473, the 
target of mTORC2, increases in KrasG12D-mediated ADM (Figure 11). Therefore, these 
data indicate that mTORC1 and mTORC2 signalling are involved in ADM formation 
in vitro.  
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Figure 9. QRT-PCR demonstrates the mRNA expression level of α-Amylase, Rbpjl, Mist1, Krt19, Rbpj 




Figure 10. (A and B) Representative phase-contrast pictures show oncogenic KrasG12D-induced ADM 
lesions, TGF-α-induced ADM lesions from wild-type acinar cells and ADM lesions from wild-type 
acinar cells (control) in 3D culture; quantitative data show the area of ADM lesions in vitro, n=3, *: 
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<0.05, unpaired t-test; QRT-PCR demonstrates the mRNA expression level of mTOR, Rptor and Rictor 
in oncogenic KrasG12D-mediated ADM lesions, TGF-α-mediated ADM lesions from wild-type acinar 




Figure 11. Western-blot analysis demonstrates the expression of p-mTORS2448, t-mTOR, Rptor, Rictor, 
p-S6S235/236, p-AktS473 and p-Ndrg1T346 in oncogenic KrasG12D-induced ADM lesions, TGF-α-induced 
ADM lesions from wild-type acinar cells and controls ADM lesions, in vitro. 
 
 
4.3 Loss of Rptor or Rictor displays no pancreatic abnormalities  
 
From in vivo and in vitro data, we might conclude that mTOR signalling plays a vital 
role in precursor lesion of PDAC. To test the functional significance of mTORC1 and 
mTORC2 activation in ADM lesions, we generated p48CreERTM; Rptorflox/flox and 
p48CreERTM; Rictorflox/flox to specifically deactivate mTORC1 and mTORC2 function in 
pancreatic acinar cells in a tamoxifen-inducible manner (Figure 12A). To trace the fate 
of recombined acinar cells, we crossed these lines with a Cre-dependent LSL-
Rosa26CAG-tdTomato reporter allele to generate p48CreERTM; Rptorflox/flox; LSL-
Rosa26CAG-tdTomato (referred to as ‘Rptor-/-’ mice) and p48CreERTM; Rictorflox/flox; LSL-
Rosa26CAG-tdTomato (referred to as ‘Rictor-/-’ mice), respectively. All recombined acinar 
cells were genetically labelled by a red fluorescent protein variant (RFP: tdTomato). All 
mice were treated with tamoxifen at 5-6 weeks of age (Figure 14). Inducible Cre-
mediated recombination efficiency was assessed by RFP immunohistochemistry 
staining (Figure 12D). The recombination efficiency was around 95%. The results of 
the western-blot analysis confirmed reduced expression of Rptor and Rictor in Rptor-/- 
and Rictor-/- pancreas after tamoxifen treatment (Figure 12B). The loss of Rptor or 
Rictor in acinar cells had no physiological impact, as reflected by random blood glucose 
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levels and body weight analysis (Figure 12C), histological analysis (Figure 12D), 
staining for endocrine (Insulin and Glucagon) and exocrine (Keratin 19 (Krt19) and α-
Amylase) markers (Figure 13). Therefore, we conclude that deletion of Rptor or Rictor 




Figure 12. (A) Diagram of inducible Cre-mediated recombination. Rptor or Rictor is specifically ablated 
in pancreas at 5 weeks old, as shown by deleting exon 6 or 11; (B) Western-blot analysis demonstrates 
the expression of Rptor and Rictor in control, Rptor-/- and Rictor-/- mice at 8 weeks old; β-actin indicates 
equal loading; (C) Quantitative data show the random blood glucose (mg/dL) and the body weight (g) of 
control, Rptor-/- and Rictor-/- mice, n>=3, unpaired t-test; (D) H&E staining shows the histology of 
pancreas from 8-week-old Rptor-/-, Rictor-/- and control mice; Representative IHC pictures show the 
expression of RFP in these animals at 8 weeks old after tamoxifen induction; Scale bars: 50 μm. 
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Figure 13. Representative IHC pictures show the exocrine (Krt19 and a-Amylase staining) and endocrine 
(Glucagon and Insulin staining) compartment of Rptor-/-, Rictor-/- and control mice at 8 weeks old; Scale 
bar: 50 μm. 
 
 
4.4 Rptor or Rictor is involved in ADM formation  
 
To determine whether Rptor or Rictor is required for ADM formation, we examined the 
impact of Rptor or Rictor ablation on ADM formation in vivo and in vitro. 
 
Firstly, we turn to caerulein induced pancreatitis mouse model. These mice were 
induced with tamoxifen at 5 weeks old to block mTORC1 or mTORC2 signalling 
separately and injected with caerulein 8 hourly for 2 consecutive days. The pancreas 
was harvested 2 or 14 days after caerulein injection (Figure 14A). ADM is the dominant 
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pancreatic responses to injury, besides leukocyte infiltration, increased separation of 
acinar lobules. All mice displayed similar histological changes, which were not 
significantly altered by Rptor or Rictor deletion (Figure 15B). In this study, 14 days 
post-injury, the pancreas was mostly restored as expected in control mice and also in 
Rptor-/- or Rictor-/- mice (Figure 15B). These data suggest that Rptor or Rictor is not 
required for inflammation-induced ADM formation and pancreatic regeneration in vivo.  
 
Figure 14. (A) 5-week-old transgenic mice were induced with tamoxifen at day 1,3,5, and injected with 
caerulein for 2 consecutive days at 8 weeks old. Pancreas was harvested for analysis 2 or 14 days after 
caerulein injection; (B) Representative H&E-stained sections show histological changes 48 hours and 14 
days after caerulein-induced pancreatitis in control, Rptor-/- and Rictor-/- pancreas; Scale bar: 50 μm. 
 
Secondly, we performed an ADM formation assay in 3D culture. Pancreatic acinar cells 
were isolated from control and Rptor or Rictor ablation mice and treated with TGF-α 
for 48h. Interestingly, Rptor or Rictor knock out acini still generated intact but smaller 
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duct-like structures compared with control acinar cells (Figures 15). Thus, this result 
suggests that both Rptor and Rictor are partially required for TGF-α-induced ADM 
formation in vitro. 
 
Figure 15. Representative IF pictures show the capacity of ADM formation (induced by TGF-α) of acinar 
cells isolated from wild type (control), Rptor-/- and Rictor-/- pancreata in 3D culture, all acinar cells are 
marked by RFP; Scale bar: 100 μm; Quantitative data shows the area of ADM lesions in vitro, n=3, 
*<0.05, unpaired t-test. 
 
 
4.5 Rptor and Rictor is crucial for KrasG12D-mediated ADM and PanIN 
formation  
 
To investigate the oncogenic role of mTORC1 and mTORC2 in PDAC, we generated 
p48CreERTM; LSL-KrasG12D/+; Rptorflox/flox; LSL-Rosa26CAG-tdTomato (referred to as 
‘KrasG12D; Rptor-/-’ mice), p48CreERTM; LSL-KrasG12D/+; Rictorflox/flox; LSL-Rosa26CAG-
tdTomato (referred to as ‘KrasG12D; Rictor-/-’ mice) and p48CreERTM; LSL-KrasG12D/+; LSL-
Rosa26CAG-tdTomato (referred to as ‘KrasG12D’ mice). These animals were treated with 
caerulein for two days after tamoxifen induction. Here, the deactivation of mTORC1 
(KrasG12D; Rptor-/-) or mTORC2 (KrasG12D; Rictor-/-) significantly inhibited ADM 
development 14 days after caerulein treatment in KrasG12D mice (as exemplified by 
H&E staining, а-Amylase and Krt19 staining, Figure 16，17，18). Furthermore, PanIN 
formation (as exemplified by Claudin 18 and Muc5ac staining) in KrasG12D; Rptor-/- and 
KrasG12D; Rictor-/- was also reduced, compared to KrasG12D mice (Figure 17，18). RFP 
IHC staining shows that the recombination efficiency is stable on the 14th day post 
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caerulein injection (Figure 16). In KrasG12D mice treated with saline, pancreas 
morphology was largely normal, although occasional PanINs were already evident by 
8 weeks of age (Figure 16). Indeed, the results of western-blot analysis revealed that 
the genetic ablation of Rptor or Rictor led to a significant reduction in the expression 
of Rptor, Rictor and mTOR as well as compromised activation of downstream targets 
of mTORC1 (p-S6S235/236) and mTORC2 (p-AktS473 and p-NdrgT346) in pancreas (Figure 
19B). Stainings for p-S6S235/236, p-NdrgT346 and p-AktS473 in pancreatic sections 
confirmed the results of western-blot analysis (Figure 19A). These data demonstrate 
that the activity of mTORC1 and mTORC2 is functionally indispensable for oncogenic 
KrasG12D-mediated ADM development.  
 
 
Figure 16. Occasional PanINs can be detected in KrasG12D mice treated with saline by 8 weeks of age 
(black arrow indicates low-grade PanIN). Representative H&E-stained sections show histological 
changes 48 hours and 14 days after caerulein-induced pancreatitis in KrasG12D, KrasG12D; Rptor-/- and 
KrasG12D; Rictor-/- pancreas; Representative IHC pictures show the expression of RFP in these animals 
(scale bars: 50 µm). 
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Figure 17. Representative IHC pictures show components of acinar cells (α-Amylase-positive), ADM 
(Krt19-positive) and PanIN (Claudin18- or Muc5ac-positive) lesions 14 days after caerulein-induced 




Figure 18. Quantitative data shows the area of acinar cells and the number of ADM and PanIN lesions 
in KrasG12D, KrasG12D; Rptor-/- and KrasG12D; Rictor-/- pancreata 14 days after caerulein-induced 
pancreatitis, n=3, *: <0.05, unpaired t-test. 
 
   




Figure 19. (A) Representative IHC pictures show stainings of p-S6S235/236, p-Ndrg1T346 and p-AktS473 14 
days after caerulein-induced pancreatitis in KrasG12D, KrasG12D; Rptor-/- and KrasG12D; Rictor-/- pancreata 
(scale bars: 50 µm); (B) Western-blot analysis demonstrates the expression of Rptor, Rictor, and mTOR 
(and p-mTORS2448) as well as activation of downstream targets of mTORC1 (p-S6S235/236) and mTORC2 
(p-Ndrg1T346, p-AktS473) in KrasG12D, KrasG12D; Rptor-/- and KrasG12D; Rictor-/- pancreata.  
 
 
4.6 Rptor and Rictor is critical for ADM formation in the presence of 
KrasG12D in vitro 
 
To analyze the effect of Rptor or Rictor on ADM formation in the presence of KrasG12D 
in vitro, freshly harvested explants from the pancreas of KrasG12D, KrasG12D; Rptor-/- 
and KrasG12D; Rictor-/- littermates were incubated with caerulein for 24 hours, we found 
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that a lot of dead single acinar cell suspended in the culture medium in KrasG12D; Rptor-
/- and KrasG12D; Rictor-/- explants compared with control. Acini clusters were seeded in 
collagen gel at 0h. At 48h, we observed round and large ADM structures from KrasG12D 
pancreas in 3D culture, however, only irregular and small ADM-like structures from 
KrasG12D; Rptor-/- and KrasG12D; Rictor-/- explants could be observed (Figure 20). We 
quantified the average area of ADM lesions and found that the size of the formed 
structures in KrasG12D; Rptor-/- and KrasG12D; Rictor-/- explants is smaller at 48h 
compared with that from KrasG12Dsamples. Taken together, the loss of Rptor or Rictor 




Figure 20. (A and B) Representative IF pictures show the capacity of ADM formation in acinar cells 
isolated from KrasG12D, KrasG12D; Rptor-/- and KrasG12D; Rictor-/- pancreas in 3D culture, all acinar cells 




4.7 mTORC1 and mTORC2 synergistically promote KrasG12D-induced 
ADM formation 
 
To test if mTORC1 and mTORC2 synergistically promote KrasG12D-induced ADM 
formation, we generated p48CreERTM; LSL-KrasG12D/+; Rptorflox/flox; Rictorflox/flox; LSL-
Rosa26CAG-tdTomato (referred to as ‘KrasG12D; Rptor-/-; Rictor-/-’ mice) compound mice 
which is double-deficient for mTORC1 and mTORC2 function. All animals were 
treated with tamoxifen at 5-6 weeks of age, and they were treated with caerulein for 
two consecutive days. Better than the phenotype of KrasG12D; Rptor-/- and KrasG12D; 
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Rictor-/- mice, there was no detectable ADM lesions two weeks after caerulein treatment 
in KrasG12D, Rptor-/-; Rictor-/- pancreas (Figure 21). To investigate the long-term impact 
of mTORC1- or mTORC2-deficiency on pancreatic carcinogenesis, we sacrificed a set 
of compound mice 24 weeks after caerulein treatment. As previously described,161 
KrasG12D animals developed high-grade PanIN lesions and numerous ADM lesions with 
occasionally visible intact acinar cells (Figure 21 and 22). The phenotype of KrasG12D; 
Rptor-/- and KrasG12D; Rictor-/- animals have slightly attenuated: more intact acinar cells 
(labelled by а-Amylase staining) and less ADM (labelled by Krt19 staining) lesions 
were observed, as compared to KrasG12D mice; however, no difference in the area of 
PanIN lesions was observed. Strikingly, the double-deficient (KrasG12D; Rptor-/-; Rictor-
/-) mice showed only a few ADM lesions and low-grade PanIN lesions (Figure 22 and 
23). Taken together, mTORC1 or mTORC2 ablation alone only transiently inhibits 
oncogenic KrasG12D-driven ADM formation. A dual deactivation of mTORC1 and 
mTORC2 is required to persistently suppress oncogenic KrasG12D-driven ADM 
development and carcinogenesis. 
 
 
Figure 21. Representative H&E-stained sections show histological changes 14days and 24 weeks after 
caerulein-induced pancreatitis in KrasG12D, KrasG12D; Rptor-/-, KrasG12D; Rictor-/- and KrasG12D; Rptor-/-; 
Rictor-/- pancreas (scale bars: 50 µm). 
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Figure 22. Representative IHC pictures show components of acinar cells (a-Amylase-positive), ADM 
(Krt19-positive) and PanIN (Claudin18- or Muc5ac-positive) lesions 24 weeks after caerulein-induced 
pancreatitis in KrasG12D, KrasG12D; Rptor-/-, KrasG12D; Rictor-/- and KrasG12D; Rptor-/-; Rictor-/- pancreas 




Figure 23. Quantitative data shows the number of acinar cells, ADM and PanIN lesions in KrasG12D, 
KrasG12D; Rptor-/-, KrasG12D; Rictor-/- and KrasG12D; Rptor-/-; Rictor-/- pancreas 24 weeks after caerulein-
induced pancreatitis (right panel), n>=5, *: <0.05, unpaired t-test. 
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4.8 Identification of differently expressed proteins in KrasG12D versus 
Rptor or Rictor ablation -KrasG12D mouse model 
 
To investigate the underlying mechanism responsible for ADM formation, we 
performed a mass spectrometry-based proteomic analysis using KrasG12D, KrasG12D; 
Rptor-/- and KrasG12D; Rictor-/- pancreatic samples 14 days after caerulein treatment. 
Similar to histological findings, the clustering analysis revealed that the proteasomes of 
KrasG12D; Rptor-/- and KrasG12D; Rictor-/- samples were comparable, but they were 
highly distinctive from KrasG12D samples (Figure 24). Next, we performed a pairwise 
comparison to identify proteins that were differentially expressed between KrasG12D and 
KrasG12D; Rptor-/- samples as well as between KrasG12D and KrasG12D; Rictor-/- samples. 
The volcano plots show the statistical significance versus the fold change for differently 
expressed proteins detected in the proteomic analysis (Figure 25). The up-regulated 
significant proteins between KrasG12D and KrasG12D; Rptor-/- mice or between KrasG12D 
and KrasG12D; Rptor-/- animals are depicted as red solid circle and green solid circle, and 
the down-regulated significant proteins are displayed as black solid circles. From these 
upregulated proteins, we pick out all proteins that were increased in KrasG12D mouse 
model and represent the distribution of them in the Venn diagram (Figure 26). Of the 
708 up-regulated proteins in KrasG12D animal, 578 were detected between KrasG12D and 
KrasG12D; Rptor-/- mice, 440 were detected between KrasG12D and KrasG12D; Rictor-/- 
mice, 310 were shared by these two sets of comparations. 
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Figure 24. The heat map presents different expression profile of all proteins tested in KrasG12D animal 




Figure 25. The volcano plots show the fold change and significance of differently expressed proteins 
detected in the proteomic analysis. Each dot in the right part of the volcano plot represent an up-regulated 
protein, displayed in red or green, each black dot represents a down-regulated protein in these two sets 
of comparison (n=3, FDR<0.05). 
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Figure 26. Venn diagram display 578 up-regulated proteins of KrasG12D sample detected in KrasG12D 




4.9 KEGG pathway enrichment analysis 
To explore the functional relevance, we analyzed the KEGG pathways using mTORC1 
and mTORC2 proteomic signatures (Figure 27; Table 6, 7). Notably, KEGG analysis 
identified six pathways: “Regulation of actin cytoskeleton”, “Lysosome”, “Focal 
adhesion” and “Fc gamma R-mediated phagocytosis”, “MAPK signaling pathway”, 
“Shigellosis”, which were shared by mTORC1 and mTORC2 proteomic signatures. As 
“Regulation of actin cytoskeleton” was the most significant pathway and as it was also 
known to be involved in ADM formation54, 162, we went on to explore this pathway. In 
particular, Arpc1b (actin related protein 2/3 complex, subunit 1B), Arpc3 (actin related 
protein 2/3 complex, subunit 3) and Arpc5 (actin related protein 2/3 complex, subunit 
5) are essential components of Arp2/3 complex which is an actin nucleator consisting 
of seven subunits.163, 164 These data suggest that the Arp2/3 complex is involved in 
oncogenic KrasG12D-driven ADM formation. 
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Figure 27. 9 enriched pathways were detected in KrasG12D versus KrasG12D; Rptor-/-, 6 enriched pathways 
were detected in KrasG12D to KrasG12D; Rictor-/- comparison. Shared up-regulated proteins related to each 
enriched pathway are presented in the table. 
 
Table 6. Enriched pathway in KrasG12D vs. KrasG12D; Rptor-/- 
 
KEGG name P value Enrichment Ben. Ho. FDR 
Regulation of actin 
cytoskeleton 
5.86950000E-07 1.6353 4.48040000E-05 
Spliceosome 5.17800000E-06 1.7716 2.37150000E-04 
MAPK signaling pathway 5.40120000E-05 1.7716 1.54610000E-03 
Focal adhesion 9.49090000E-05 1.6299 2.41490000E-03 
Lysosome 2.28710000E-04 1.5748 5.23750000E-03 
Pathogenic Escherichia 
coli infection 
2.53460000E-04 1.6784 5.27670000E-03 
Fc gamma R-mediated 
phagocytosis 
4.30600000E-04 1.6732 7.04330000E-03 
Shigellosis 4.30600000E-04 1.6732 7.58510000E-03 
Bacterial invasion of 
epithelial cells 
7.28690000E-04 1.6674 9.81580000E-03 
 
 
Table 7. Enriched pathway in KrasG12D vs. KrasG12D; Rictor-/- 
 
KEGG name P value Enrichment Ben. Ho. FDR 
Regulation of actin 
cytoskeleton 
4.03360000E-07 1.6705 2.94460000E-05 
Focal adhesion 2.92560000E-05 1.6705 1.28140000E-03 
Fc gamma R-mediated 
phagocytosis 
4.97550000E-05 1.6705 1.55660000E-03 
Lysosome 9.59690000E-05 1.5978 2.62710000E-03 
MAPK signaling pathway 2.43330000E-04 1.6705 4.84450000E-03 
Shigellosis 4.12230000E-04 1.6705 6.01850000E-03 
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4.10 Validation of mass spectrometry data in vivo and in vitro 
 
Firstly, we investigated the expression of several Arp2/3 complex components (Arp2, 
Arp3 and Arpc1b) in pancreatic tissues from KrasG12D, KrasG12D; Rptor-/- and KrasG12D; 
Rictor-/- mice 14 days after caerulein treatment. Accordingly, the results of western-blot 
analysis revealed that the expression of these Arp2/3 complex components was reduced 
in both KrasG12D; Rptor-/- and KrasG12D; Rictor-/- samples, compared to KrasG12D 
samples (Figure 28A). In vitro, Arp2, Arp3 and Arpc1b expression was higher in 
KrasG12D-mediated ADM lesions, as compared to TGF-α-induced ADM lesions from 
wild-type acinar cells and control ADM lesions (Figure 28B). Finally, the expression of 
ARPC1B, ARP2 and ARP3 was also higher in human CP tissues than that in the normal 
pancreas (Figure 28C). Also, we confirmed these data using IHC staining analysis 
(Figure 28D). F-actin was localized on both apical and basal part of these ADM lesions 
of KrasG12D pancreas in vivo and in vitro (Figure 29). 
    
 
 
Figure 28. (A) Western-blot analysis confirms the reduced expression of Arpc1b, Arp2 and Arp3 in 
KrasG12D; Rptor-/- and KrasG12D; Rictor-/-, compared to KrasG12D samples; (B) Western-blot analysis 
demonstrates the expression of Arpc1b, Arp2 and Arp3 in oncogenic KrasG12D-induced ADM lesions, 
TGF-α-induced ADM lesions from wild-type acinar cells and ADM lesions from wild-type acinar cells, 
in vitro; (C) Western-blot analysis demonstrates the expression of ARPC1B, ARP2 and ARP3 in normal 
and chronic pancreatitis tissues. GAPDH is served as equal loading; (D) Representative IHC pictures 
show the staining of Arp2 andArp3 in human chronic pancreatitis tissue and normal human pancreas 
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Figure 29. Representative IF pictures show the F-actin and Krt19 localization in the ADM lesions of 
KrasG12D pancreas two weeks after caerulein injection and in the ADM lesion formed by isolated KrasG12D 
acinar cells in vitro (scale bars: 25 µm). 
 
 
4.11 Loss of Arpc4 displays no pancreatic abnormalities 
 
From the KEGG pathway enrichment analysis, we noticed that the regulation of actin 
cytoskeleton is the most significant pathway involved in ADM formation. In this 
pathway, many proteins correlated with actin cytoskeleton are upregulated. For 
example, Arp2/3, Cofilin 1, Profilin 2 and Tmsb4x, most of them are actin-binding 
proteins. Therefore, we choose the Arp2/3 complex as the main target to study its role 
in precursor lesion of PDAC. Moreover, it is reported that the y-branching of actin 
filament network mediated by Arp2/3 complex is ideally suited for generating 
mechanical tension required in lamellipodia formation.165 Thus, we hypothesized that 
the tension-generating property of branch network mediated by Arp2/3 complex might 
be responsible for creating the apico-basal tension redistribution in the process of ADM 
formation.  
 
To test this, we crossed an Arpc4flox/flox (actin-related protein 2/3 complex, subunit 4) 
line with p48CreERTM to generate p48CreERTM; Arpc4flox/flox (referred to as ‘Arpc4-/-’ 
mice). Previous studies have proved that the loss of Arpc4 subunit completely 
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deactivated the function of Arp2/3 complex.157 All mice were treated as above 
mentioned. The results of western-blot analysis confirmed reduced expression of Arpc4, 
Arp2, Arp3 and Arpc1b in Arpc4-/- mice after tamoxifen treatment (Figure 30A). The 
loss of Arp2/3 complex function in acinar cells had no significant impact on pancreatic 
physiology, as reflected by histological analysis, staining for endocrine (Insulin and 
Glucagon) and exocrine (Keratin 19 (Krt19) and α-Amylase) markers, random blood 





Figure 30. (A) Western-blot analysis demonstrates the expression of Arpc1b, Arp2, Arp3 and Arpc4 in 
wildtype (control) and Arpc4-/- pancreata; (B) Quantitative data show the random blood glucose (mg/dL) 
and the body weight (g) of control and Arpc4-/- mice; n=3, unpaired t-test; (C) Representative IHC 
pictures show the exocrine (Krt19 and α-Amylase staining) and endocrine (Glucagon and Insulin staining) 
compartment of these animals (scale bars: 50 µm).  
 
 
4.12 Arpc4 is required for ADM formation 
 
To test if Arpc4-/- mice are generally resistant to ADM formation, we treated them with 
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caerulein for two consecutive days and sacrificed 48 hours and 14 days after caerulein 
treatment. The pancreas of all Arpc4-/- mice was fully regenerated on day 14, indicating 
that the loss of Arp2/3 complex function did not influence organ regeneration. Notably, 
the number of ADM lesions was dramatically reduced in Arpc4-/- mice 48 hours after 
caerulein treatment, as compared to control animals (Figure 31A). Thus, acinar cells 
deficient for Arp2/3 complex function are protected against inflammation-induced 
ADM formation.  
 
After in vivo experiments, pancreatic acinar cells were isolated from control and Arpc4 
ablation mice and treated with TGF-α for 48h. Ductal-like structure generated from 
Arpc4 knock out acini is smaller compared with control (Figures 31B). This result 
suggests that the inhibitory effect of Arp2/3 complex on ADM formation is cell 
autonomous in vitro. Overall, the data from in vivo and in vitro indicate that Arp2/3 




Figure 31. (A) Representative H&E-stained sections show histological changes 48 hours and 14 days 
after caerulein-induced pancreatitis in control and Arpc4-/- pancreas (scale bars: 50 µm); (B) 
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Representative pictures show the capacity of ADM formation (induced by TGF-α) of acinar cells isolated 
from control and Arpc4-/- pancreas in 3D culture. Quantitative data shows the area of ADM lesions in 
vitro, *<0.05, unpaired t-test. 
 
 
4.13 The inactivation of Arp2/3 complex completely blocks oncogenic 
KrasG12D-mediated ADM formation 
 
To investigate the potential oncogenic role of Arp2/3 complex, we generated 
p48CreERTM; LSL-KrasG12D/+; Arpc4flox/flox (referred to as ‘KrasG12D; Arpc4-/-’ mice). 
After tamoxifen induction, all animals were treated with caerulein and subjected to 
histopathological characterization 14 days after treatment. Compellingly, all KrasG12D; 
Arpc4-/- pancreas were completely devoid of ADM and PanIN lesions, as compared to 
KrasG12D pancreas (Figure 32A, 32C, as exemplified by H&E staining, а-Amylase, 
Krt19, Claudin 18 and Muc5ac staining). The results of western-blot analysis revealed 
that the genetic ablation of Arpc4 led to a dramatic reduction in the expression of Arpc4, 
Arp2, Arp3 and Arpc1b in KrasG12D; Arpc4-/- pancreas, as compared to KrasG12D 
pancreas (Figure 32B). Besides, Rac1 expression was significantly reduced in KrasG12D; 
Arpc4-/- pancreas. Except for Rictor and p-AktS473 (the reduction in KrasG12D; Arpc4-/- 
samples), no difference in the activation of downstream targets for mTORC1 (p-
mTORS2448, Rptor and p-S6S235/236) and mTORC2 (p-mTORS2448 and p-NdrgT346) was 
observed between KrasG12D and KrasG12D; Arpc4-/- pancreas (Figure 32B). Consistently, 
KrasG12D; Arpc4-/- acinar cells showed a compromised capacity in forming ADM lesions 
in vitro, as compared to KrasG12D acinar cells (Figure 33). It is reported that the myosin 
activity (as exemplified by phospho-Myosin Light Chain 2Ser19, p-MLC2S19) is higher 
apically than basally in acinar cells; however, this gradient was lost in the ADM lesions 
of KrasG12D pancreata.166 Here IF shows that KrasG12D; Arpc4-/- acinar cells maintained 
acinar phenotype (positive for α-Amylase staining) with focused myosin activity 
(labelled by p-MLC2S19, Figure 34) in 3D culture. In comparison, KrasG12D acinar cells 
assumed ductal phenotype (positive for Krt19) with basally enhanced myosin activity 
(positive for p-MLC2S19 staining) in vitro, underscoring the importance of apical-basal 
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tension redistribution in instructing ADM formation (Figure 34). Taken together, these 
data demonstrate a crucial role of Arp2/3 complex in ADM formation by redistributing 





Figure 32. (A) Representative H&E-stained sections show histological changes 14 days after caerulein-
induced pancreatitis in KrasG12D and KrasG12D; Arpc4-/- pancreas (scale bars: 50 µm); (B) Western-blot 
analysis demonstrates the expression of p-mTORSer2448, pAktS473, p-Ndrg1T346, p-S6S235/236, Rictor, Rptor, 
Arpc1b, Arp2, Arp3, Arpc4 and Rac1 14 days after caerulein-induced pancreatitis in KrasG12D and 
KrasG12D; Arpc4-/- pancreas; (C) Representative IHC pictures show components of acinar cells (α-
Amylase-positive), ADM (Krt19-positive) and PanIN (Claudin18- or Muc5ac-positive) lesions 14 days 
after caerulein-induced pancreatitis in KrasG12D and KrasG12D; Arpc4-/- pancreas (scale bars: 50 µm). 
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Figure 33. Representative phase contrast pictures show the capacity of ADM formation of acinar cells 
isolated from KrasG12D and KrasG12D; Arpc4-/- pancreas in 3D culture; quantitative data show the area of 
ADM lesions in vitro, n=3, *: <0.05, unpaired t-test. 
  
 
Figure 34. Representative IF pictures show p-MLC2S19, Krt19 and а-Amylase staining in ADM lesions 
formed by acinar cells isolated from KrasG12D and KrasG12D; Arpc4-/- pancreas in 3D culture.   
 
 
4.14 mTORC2 activates the activity of Arp2/3 complex via Akt/Rac1 
signal axis while mTORC1 controls the protein synthesis of Rac1/Arp3  
 
We went on to investigate how mTORC1 and mTORC2 affect the activity of Arp2/3 
complex. As illustrated earlier, since Rac1 is indispensable for KrasG12D-driven ADM 
formation, the phenotype of mTORC2-deficient mice can be attributed to damped Rac1 
activity.54, 162 mTORC2 activates Rac1 activity through two substrates: Akt and Pkcα.167, 
168 Rac1 promotes the activity of the Arp2/3 complex via WAVE proteins (WASP-
family verprolin-homologous proteins, Figure 33A).169 Thus, we hypothesise that: 1). 
inhibition of these signal pathways blocks ADM formation of isolated KrasG12D acinar 
cells; 2). activation of these signal pathways reconstitutes the ADM phenotype in 
isolated KrasG12D; Rictor-/- acinar cells in vitro. To test this, a variety of pharmaceutical 
inhibitors against Akt1/2 (Akti-1/2), Pkcα (BIM XI), Rac1 (EHT 1864), Arp2/3 (CK-
666), actin polymerization (Cytochalasin D) were used to test their capacities in 
inhibiting KrasG12D-induced ADM formation in 3D culture (Figure 35A). This analysis 
revealed that inhibition of Akt, Rac1, Arp2/3 complex and actin polymerization 
effectively block isolated KrasG12D acinar cells in forming ADM in vitro whereas 
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inhibition of Pkcα had no effect (Figure 35A). These data suggest that 
mTORC2/Akt/Rac1/Arp2/3 complex signal constitutes a crucial pathway mediating 
ADM formation in isolated KrasG12D acinar cells. Indeed, Rac1 pull-down activation 
assay confirmed that both Rac1 expression and activation (GTP-bound) were 
dramatically reduced in both KrasG12D; Rictor-/- and KrasG12D; Rptor-/- pancreatic tissues, 
as compared to KrasG12D pancreas (Figure 35B). Furthermore, inhibition of either Akt 
(Akti-1/2) or Rac1 (EHT 1864) reduced consistently phosphorylation levels of p-
AktS473 and expression levels of Rac1, Arp2, Arp3 and Arpc1b in the isolated KrasG12D 
acinar cells. No such effect was observed for Pkcα inhibition (Figure 36).  
 
Consistently, activation of Akt signalling by an Akt activator (SC 79) reconstituted 
ADM phenotype in isolated KrasG12D; Rictor-/- acinar cells, but not in isolated KrasG12D; 
Rptor-/- acinar cells (Figure 37A). The SC 79 treatment increased phosphorylation 
levels of p-AktS473 and it induced Rac1 expression and activation simultaneously in 
KrasG12D; Rictor-/- acinar cells (Figure 37B, 38A). In addition, the SC 79 treatment 
activated Akt signaling in KrasG12D; Rptor-/- acinar cells (Figure 37C). To confirm that 
Rac1 is responsible for ADM formation induced by Akt activation in KrasG12D; Rictor-
/- acinar cells, a combinational treatment of Akt activator and Rac1 inhibitor was applied. 
As such, the additional Rac1 inhibition completely blocked the ability of Akt activator 
in inducing ADM formation in KrasG12D; Rictor-/- acinar cells (Figure 38B). Thus, 
mTORC2 promotes the function of Arp2/3 complex through Akt/Rac1 pathway in 
driving KrasG12D-mediated ADM formation.  
 
The Akt activity in KrasG12D and KrasG12D, Rptor-/- pancreas was comparable, and Akt 
activation failed to reconstitute ADM phenotype in isolated KrasG12D, Rptor-/- acinar 
cells (Figure 37A). However, Rac1 expression (and activity) together with components 
of Arp2/3 was indeed reduced in KrasG12D, Rptor-/- pancreas, as compared to KrasG12D 
pancreas. Thus, these phenomena in mTORC1-deficient mice cannot be explained by 
Akt signalling. As mTORC1 is a master complex responsible for protein synthesis, we 
hypothesise mTORC1 is accountable for the protein synthesis of Rac1 and Arp2/3 
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complex components. To test this, we performed a protein synthesis assay using isolated 
KrasG12D acinar cells in 3D culture. As such, the freshly prepared acinar cells were 
added to 3D culturing condition to form ADM lesions for 12 hours. To determine the 
protein synthesis rates of Rac1 and Arp2/3 complex components, ADM lesions were 
treated with cycloheximide (CHX: an inhibitor of protein synthesis) then released from 
CHX and harvested at 0-, 0.5-, 1-, 2- and 3-hours in the presence of mTORC1 inhibitor 
(Rapamycin, Figure 39). This analysis revealed that the activity of mTORC1 is 
responsible for the protein synthesis of Rac1 and Arp3, but not for Arp2, Arpc1b (Figure 
39). As an internal control, Rapamycin treatment reduced p-S6S235/236 levels in these 




Figure 35. (A) Representative IF pictures show the capacity of ADM formation of acinar cells isolated 
from KrasG12D pancreas under the treatment of Pkcα (BIM XI), Akt (Akti-1/2), Rac1 (EHT1864), Arp2/3 
(CK-666) and actin (Cyt D) inhibition; quantitative data shows the area of ADM lesions in vitro (low 
panel), n=3, *: <0.05, unpaired t test; (B) Rac1 pull-down assay shows Rac1 activation (GTP-Rac1) and 
expression 14 days after caerulein-induced pancreatitis in KrasG12D, KrasG12D; Rptor-/- and KrasG12D; 




Figure 36. Western-blot analysis show the expression of p-AktS473, Rac1, Arp2, Arp3, Arpc1b in 
KrasG12D-induced ADM cells treated with control (PBS), or Akt1/2 (Akti-1/2), or p-Pkcα (BIM XI) or 
Rac1 inhibitor (EHT 1864). 
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Figure 37. (A) Representative IF pictures show the capacity of ADM formation of acinar cells isolated 
from KrasG12D; Rictor-/- and KrasG12D; Rptor-/- pancreas under the treatment of control and Akt activator 
(SC79); quantitative data shows the area of ADM lesions in vitro (low panel), n=3, *: <0.05, unpaired t 
test; (B) Western-blot analysis shows the activation of Akt pathways (p-AktS473) in KrasG12D; Rictor-/- 
acinar cells after the treatment of Akt acivator (SC79); (C) Western-blot analysis shows the activation of 




Figure 38. (A) Rac1 pull-down assay shows the active Rac1 (GTP-Rac1) in KrasG12D; Rictor-/- acinar 
cells after the treatment of Akt acivator (SC79); (B) Representative IF pictures show the capacity of 
ADM formation of acinar cells isolated from KrasG12D; Rictor-/- pancreata under the treatment of control, 
Akt activator (SC79), Rac1 inhibtor (EHT 1864) and both; quantitative data shows the area of ADM 
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Figure 39. Western-blot analysis of block-and-release assay shows the expression of Arpc1b, Arp2, Arp3, 
Rac1, p-S6S235/236 and S6 under the treatment of control or Rapamycin; one out of three independent 
experiments is shown, quantitative data shows the relative density of Arp3, Rac1 and p-S6S234/236 at 2h 
and 3h timepoint, n=3, *: <0.05, unpaired t-test. 




5. Discussion  
 
 
In human PDAC, more than 80% of cases carry Kras mutation which persistently 
activates the downstream effectors to promote tumour growth, and metastasis.170 mTOR 
signalling is a downstream pathway of MAPK pathway and vital for cell growth and 
survival. mTOR activation is widely implicated in tumorigenesis. The fatality of PDAC 
urges researchers to find a solution to make early diagnosis and treatment. In our 
previous study, mTOR signalling promotes PDAC development in the mouse model 
and is overexpressed in most human PDAC samples.171 In this study, we observed that 
the activation of mTOR signaling is an early event associated with pancreatic 
carcinogenesis that is visible already in pre-neoplastic ADM lesions. 
 
Previously, it has been published that the TGF-α treatment or the expression of 
oncogenic Kras promotes ADM formation at a conversion rate of around 75% without 
the pre-treatment of caerulein.172-175 Here, we optimized the assay protocol by 
incubating the isolated pancreatic acinar cells in 2D culture medium with caerulein for 
24 hours before seeding them in collagen gel. As such, the ADM formation at higher 
conversion rate (data is not shown) is observed in the absence of mutant Kras 
expression or TGF-α stimulation. It was verified by measuring the ADM markers via 
QRT-PCR assay. This optimized assay protocol enabled us to investigate the phenotypic 
difference between the physiological ADM lesions formed by wild-type acinar cells 
and the oncogenic ADM lesions by acinar cells with oncogenic KrasG12D expression.  
However, how caerulein promotes the ability of acinar cells to form ADM lesions in 
vitro is still elusive.  
 
In this study, in vivo and in vitro data indicate that the mTOR signaling is implicated in 
the precursor lesion of PDAC. Hence, we used the transgenic mouse model to study the 
impact of mTORC1 and mTORC2 on the KrasG12D-driven ADM formation. Given the 
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known important physiological function of mTORC1 and mTORC2 in pancreas (e.g. 
endocrine function107, 108), we did not use the conventional pancreas-specific Cre such 
as p48Cre to ablate Rptor and Rictor, respectively. Instead, we turned to an inducible 
mouse model. It was reported that the Ptf1aCreER allele specifically targets the acinar 
cell compartments and recombine the KrasG12D allele effectively.15 In this study, RFP, 
as a reporter, is employed to monitor the creERTM-mediated recombination efficiency. 
After the TAM induction, the pancreas of the reporter strain appears to be red. Based 
on the immunohistochemistry analysis of RFP, he recombination efficiency is as high 
as approximately 95%. Previously, it has been reported that the conventional creER-
mediated recombination efficiency in the pancreatic acinar cell is as low as 10%.15 The 
published experience showed that the creERTM construct is about 10-fold more 
sensitive to induction than the creER.21 Moreover, in smooth muscle, the creERTM-
mediated recombination efficiency is up to 100% .176 In this study, the creERTM-
mediated recombination efficiency is sufficient and stable, which is the experimental 
prerequisite to stably reproduce the presented results  
 
In this study, we found that the inhibition of mTORC1 or mTORC2 signalling alone 
only partially block the KrasG12D-driven ADM formation in vivo; however, the dual 
inhibition of mTORC1 and mTORC2 was required to persistently inhibit the ADM and 
PanIN formation. These findings are similar to the observations of mTOR inhibitor in 
clinical trials: rapalogs, as the first generation of mTOR inhibitor, is sensitive to 
mTORC1. The monotherapy with rapalogs failed in the majority of primary solid 
tumours due to the feedback activation of insulin/PI3K/Akt signaling when mTORC1 
signalling is blocked for a long time.177 Later on, the dual mTORC1/2 inhibitors were 
developed as targeted anticancer agents. The ATP-competitive mTOR kinase inhibitor, 
the second-generation inhibitor, blocks the activity of  mTORC1 and mTORC2 
entirely by inhibiting the catalytic activity of mTOR.123 In preclinical research, the dual 
mTORC1/2 inhibitor was used in mouse model, and PDAC progression was 
significantly delayed.156 The results of clinical trial testing the effectiveness of dual 
mTORC1/2 inhibitor are also promising.178, 179 All these findings support that both 
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mTORC1 and mTORC2 signalling play an essential role in promoting oncogenic Kras-
mediated PDAC onset and progression. .  
 
Based on KEGG pathway enrichment analysis, we identified the regulation of actin 
cytoskeleton is the most correlated pathway in the oncogenic KrasG12D-mediated ADM 
formation. This finding is consistent with the previous study.54, 166 It is reported that the 
actin rearrangement is strongly associated with ADM formation. F-actin redistributes 
to the basolateral side from the apical, leading to the loss of cell polarity during the 
ADM formation. The inhibition of actin cytoskeleton results in an impaired ADM 
formation. In our study, we verified these findings in our 3D culture system. It is 
reported that the actin cytoskeleton remodeling is not only critical in the ADM 
formation, but also in the epithelial-mesenchymal transition (EMT) and cancer 
metastasis.180 During EMT, the actin rearrangement support the dynamic cell 
elongation and provide the directional motility, contributing to a migratory phenotype 
of cancer cells.181 In metastasis, cancer cell has a high plasticity to migrate from primary 
tumour site to distant tissue; the acquisition of migratory capacity dependents on the 
actin reorganization.  
 
Cell morphology altered in the process of ADM formation, EMT and cancer metastasis. 
It is reported that of several cellular forces drive morphogenesis. The genetic screens 
uncover that the key driver underpinning morphogenesis is the actomyosin cytoskeleton, 
composed of actin and myosin. In the network, myosin can generate contractile force.182 
Hendrik A. and his colleagues found that the myosin activity was mainly apically 
located in pancreatic acinar cells, but upon transformation, it redistributes to the 
basolateral side and concentrates on both sides of duct-like cells.166 In this study, we 
identified the same distribution of myosin activity in oncogenic KrasG12D-mediated 
ADM lesions. Actin filaments can produce pushing (protrusive) forces on the leading 
edge of cells. Branched network-mediated protrusion (lamellipodia) generates more 
pushing forces than parallel bundles-mediated protrusion (filopodia), and function as a 
main cellular motor to move the cutting edge forward in cell migration.183 In 
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lamellipodia, Arp2/3 complex, one regulator of the actin cytoskeleton, promote 
dendritic nucleation and generate the branched network. It creates a daughter filament 
on the side of mother filament at an angle of around 70°.184, 185 In this way, being 
anchored on mother filament, daughter filament transmits the force of actin 
polymerization onto membrane much more effectively. Also, according to the 
calculation in a specific model, pushing force imposed at an angle to the membrane also 
promote protrusion much better.183, 186 From previous study, we can conclude that 
Arp2/3 complex play an essential role in cell morphogenesis. In this study, we 
confirmed this view by finding that impaired Arp2/3 complex blocked oncogenic 
KrasG12D-mediated ADM formation in vivo and in vitro. 
 
In the KEGG pathway enrichment analysis, the expression of Rac1is also increased in 
in KrasG12D pancreata. RAC1 is widely involved in solid tumours; it promotes cancer 
cell proliferation, metastasis and drug-resistance.187 Around three decades ago, it was 
found that Rac1 regulates the actin cytoskeleton organization in fibroblast.188 In gastric 
adenocarcinoma, Rac1 inhibition block the EMT process and the acquisition of stem-
like cells phenotype.189 In colorectal cancer, mTORC1 and mTORC2 promote EMT, 
motility and metastasis via Rac1 signalling.190 Moreover, in breast cancer, mTORC2 
activates Akt and PKC pathways, both of which converge on the Rac1 to promote cell 
invasion and motility.168 Besides, in our study, Rac1 activity is upregulated in KrasG12D 
pancreata after caerulein treatment. It was reported that Rac1 promotes the KrasG12D-
mediated ADM formation by regulating actin cytoskeleton,54 however, the mechanism 
underlying the Rac1-mediated actin rearrangement was not well addressed. 
Nevertheless, the downstream of Rac1 is well studied in lamellipodia, which provides 
the dominant force in cell motility as we discussed above. It was found that activated 
Rac1 directly recruits the WAVE complex at the plasma membrane, and subsequently 
activates Arp2/3 complex, which mediates the branched actin network.191 In the KEGG 
pathway enrichment analysis, both of Rac1 and Arp2/3 complex are increased in Kras-
mediated ADM formation, imply the critical role of Rac1-WAVE-Arp2/3-mediated 
cytoskeleton reorganization in this particular scenario. Another alternative mechanism 
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for Rac1-mediated actin rearrangement is by activating PAK (p21-activated kinase). 
PAK1 is a known regulator of actin dynamics and cell motility.192 Since PAK1 is not 
appeared in our proteomic analysis , the Rac1-PAK-mediated actin polymerization may 
not be involved in the KrasG12D-mediated ADM formation.  
 
In this study, we provided descriptive and functional evidence delineating a crucial role 
of Arp2/3 complex in oncogenic KrasG12D-mediated ADM formation. Through a non-
redundant regulatory system, the function of the Arp2/3 complex is controlled by 
oncogenic mTORC1 and mTORC2. In particular, the Arp2/3 complex-mediated actin 
polymerization is responsible for generating apical-basal tension redistribution, it acts 
as an “incipient” instruction cue for inducing ductal morphology of acinar cells. 
 
Previously, we demonstrated an oncogenic property of mTORC1 signalling in 
established PDAC. As such, the KrasG12D/Mek-mediated mTORC1 signalling promotes 
a highly metastatic subtype of PDAC.153 Further analysis uncovered that the oncogenic 
activity of KrasG12D/Mek-mediated mTORC1 signalling partially relied on Aldh1a3 
(aldehyde dehydrogenase 1 family member A3) function. Here, we demonstrated that 
the oncogenic activity of mTORC1 in early carcinogenesis rather depended on its 
regulatory function on Rac1 and Arp2/3 complex in polymerizing actin cytoskeleton. 
Thus, the oncogenic Kras-mediated mTORC1 signalling is per se oncogenic; however, 
it may use distinct downstream effector to promote tumour progression depending on 
the specific stage of PDAC development. Compared to mTORC1 signalling, the 
function of mTORC2 signalling is less pleiotropic. Previously, Driscoll and co-workers 
reported that deactivation of mTORC2 signalling by Rictor deletion specifically 
impaired PanIN progression to invasive carcinoma in a well-defined mouse model of 
PDAC.156 It is observed that mTORC2 deactivation led to an elevation of multiple CDK 
(Cyclin-dependent kinase) inhibitors such as p16Ink4a and p21Cip1 in PanIN lesions, 
thereby, blunted PanIN progression. However, it remains elusive how mTORC2 
signalling would affect the function of CDK inhibitors. Alternatively, we provided 
evidence that the oncogenic activity of mTORC2 signalling could also be attributed to 
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its classic role in regulating actin cytoskeleton via Akt/Rac1 signal axis. However, this 
oncogenic function of mTORC2 signalling is particularly crucial for oncogenic Kras-
driven ADM formation rather than PanIN progression. Collectively, these data argue 
for a context-dependent role of oncogenic mTORC1 and mTORC2 signalling in a 
different stage of PDAC development.  
 
The Arp2/3 complex is the first identified actin nucleator whose function is unique that 
it binds to the sides of existing actin filament and promotes novel actin polymerization 
to form branching filament network, leading to so-called y-branching.193, 194 Notably, 
this y-branching of filament network by Arp2/3 complex is ideally suited for generating 
mechanical tension required in a variety of biological circumstances such as 
lamellipodia formation.165 Thus, it is conceivable that this tension-generating property 
of y-branching filament is responsible for creating the apico-basal tension redistribution 
in the process of oncogenic ADM formation. For the first time, we demonstrated that 
the Arp2/3 complex is the converging point of two major oncogenic pathways of PDAC: 
mTORC1 and mTORC2. Thus, targeting of the Arp2/3 complex may circumvent the 
feedback responses elicited by direct mTOR inhibition.153, 195 The effectiveness of such 
therapies should be tested in a translational setting. Certainly, the function of the Arp2/3 














6. Summary  
 
 
Previously, we and others have provided genetic evidence defining the oncogenic 
function of both mTORC1 and mTORC2 in PDAC. Now, we observed that mTORC1 
and mTORC2 were particularly activated in pre-neoplastic ADM lesions. The 
deactivation of mTORC1 or mTORC2 activity compromised oncogenic KrasG12D-
induced ADM development. The proteomic analyses identified the Arp2/3 complex, as 
the common downstream effector of mTORC1 and mTORC2 signalling. The Arp2/3 
complex is the first identified actin nucleator consisting of seven proteins: Arp2, Arp3 
and Arpc1-Arpc5. In the ADM development, it mediates y-branching of actin filament 
responsible for generating apical-basal tension redistribution. Mechanistically, 
mTORC1 is responsible for the direct protein synthesis of Rac1 and Arp3 while 
mTORC2 promotes the activity of Arp2/3 complex by Akt/Rac1 signal axis. Finally, 
deactivation of Arp2/3 complex by pancreas-specific Arpc4 ablation completely blocks 
oncogenic KrasG12D-induced ADM formation. Thus, we defined a dual, yet non-
redundant, regulatory function of mTORC1 and mTORC2 on Arp2/3 complex in 
promoting ADM formation.







1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 
2014;64:9-29. 
2. Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet 2016;388:73-85. 
3. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. 
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and 
meta-analysis of response and resection percentages. PLoS Med 
2010;7:e1000267. 
4. Spanknebel K, Conlon KC. Advances in the surgical management of pancreatic 
cancer. Cancer J 2001;7:312-23. 
5. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths 
to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the 
United States. Cancer Res 2014;74:2913-21. 
6. Luttges J. [What's new? The 2010 WHO classification for tumours of the 
pancreas]. Pathologe 2011;32 Suppl 2:332-6. 
7. Wood LD, Hruban RH. Pathology and molecular genetics of pancreatic 
neoplasms. Cancer J 2012;18:492-501. 
8. Le N, Sund M, Vinci A. Prognostic and predictive markers in pancreatic 
adenocarcinoma. Dig Liver Dis 2016;48:223-30. 
9. Perkhofer L, Ettrich TJ, Seufferlein T. Pancreatic Cancer: Progress in Systemic 
Therapy. Gastrointest Tumors 2014;1:167-79. 
10. Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12 mutations occur very 
frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-82. 
11. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the 
exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54. 
12. Noe M, Brosens LA. Pathology of Pancreatic Cancer Precursor Lesions. Surg 
Pathol Clin 2016;9:561-580. 
13. Pin CL, Ryan JF, Mehmood R. Acinar cell reprogramming: a clinically 
important target in pancreatic disease. Epigenomics 2015;7:267-81. 
14. Yamaguchi J, Yokoyama Y, Kokuryo T, et al. Cells of origin of pancreatic 
neoplasms. Surg Today 2018;48:9-17. 
15. Kopp JL, von Figura G, Mayes E, et al. Identification of Sox9-dependent acinar-
to-ductal reprogramming as the principal mechanism for initiation of pancreatic 
ductal adenocarcinoma. Cancer Cell 2012;22:737-50. 
16. Gidekel Friedlander SY, Chu GC, Snyder EL, et al. Context-dependent 
transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 
2009;16:379-89. 
17. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D 
cooperate to promote chromosomal instability and widely metastatic pancreatic 
References                                                          87                                                                                                                                                                                                                                                 
ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83. 
18. Lee JW, Komar CA, Bengsch F, et al. Genetically Engineered Mouse Models of 
Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-
Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-
oncology Drug Discovery. Curr Protoc Pharmacol 2016;73:14.39.1-14.39.20. 
19. Feil R, Brocard J, Mascrez B, et al. Ligand-activated site-specific recombination 
in mice. Proc Natl Acad Sci U S A 1996;93:10887-90. 
20. Feil S, Valtcheva N, Feil R. Inducible Cre mice. Methods Mol Biol 
2009;530:343-63. 
21. Indra AK, Warot X, Brocard J, et al. Temporally-controlled site-specific 
mutagenesis in the basal layer of the epidermis: comparison of the recombinase 
activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. 
Nucleic Acids Res 1999;27:4324-7. 
22. Kuhbandner S, Brummer S, Metzger D, et al. Temporally controlled somatic 
mutagenesis in smooth muscle. Genesis 2000;28:15-22. 
23. Kopinke D, Brailsford M, Pan FC, et al. Ongoing Notch signaling maintains 
phenotypic fidelity in the adult exocrine pancreas. Dev Biol 2012;362:57-64. 
24. Desai BM, Oliver-Krasinski J, De Leon DD, et al. Preexisting pancreatic acinar 
cells contribute to acinar cell, but not islet beta cell, regeneration. J Clin Invest 
2007;117:971-7. 
25. De La OJ, Emerson LL, Goodman JL, et al. Notch and Kras reprogram 
pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U 
S A 2008;105:18907-12. 
26. Bouabe H, Okkenhaug K. Gene targeting in mice: a review. Methods Mol Biol 
2013;1064:315-36. 
27. Pan FC, Bankaitis ED, Boyer D, et al. Spatiotemporal patterns of 
multipotentiality in Ptf1a-expressing cells during pancreas organogenesis and 
injury-induced facultative restoration. Development 2013;140:751-64. 
28. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: a matter 
of differentiation and development? Gut 2012;61:449-58. 
29. Baer R, Cintas C, Dufresne M, et al. Pancreatic cell plasticity and cancer 
initiation induced by oncogenic Kras is completely dependent on wild-type PI 
3-kinase p110alpha. Genes Dev 2014;28:2621-35. 
30. Shi G, DiRenzo D, Qu C, et al. Maintenance of acinar cell organization is critical 
to preventing Kras-induced acinar-ductal metaplasia. Oncogene 2013;32:1950-
8. 
31. Means AL, Meszoely IM, Suzuki K, et al. Pancreatic epithelial plasticity 
mediated by acinar cell transdifferentiation and generation of nestin-positive 
intermediates. Development 2005;132:3767-76. 
32. Liu J, Akanuma N, Liu C, et al. TGF-beta1 promotes acinar to ductal metaplasia 
of human pancreatic acinar cells. Sci Rep 2016;6:30904. 
33. Krah NM, De La OJ, Swift GH, et al. The acinar differentiation determinant 
PTF1A inhibits initiation of pancreatic ductal adenocarcinoma. Elife 2015;4. 
34. Martinelli P, Madriles F, Canamero M, et al. The acinar regulator Gata6 
References                                                          88                                                                                                                                                                                                                                                 
suppresses KrasG12V-driven pancreatic tumorigenesis in mice. Gut 
2016;65:476-86. 
35. Zhu L, Tran T, Rukstalis JM, et al. Inhibition of Mist1 homodimer formation 
induces pancreatic acinar-to-ductal metaplasia. Mol Cell Biol 2004;24:2673-81. 
36. Hendley AM, Provost E, Bailey JM, et al. p120 Catenin is required for normal 
tubulogenesis but not epithelial integrity in developing mouse pancreas. Dev 
Biol 2015;399:41-53. 
37. Kopp JL, Dubois CL, Schaffer AE, et al. Sox9+ ductal cells are multipotent 
progenitors throughout development but do not produce new endocrine cells in 
the normal or injured adult pancreas. Development 2011;138:653-65. 
38. Furuyama K, Kawaguchi Y, Akiyama H, et al. Continuous cell supply from a 
Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. 
Nat Genet 2011;43:34-41. 
39. Prevot PP, Simion A, Grimont A, et al. Role of the ductal transcription factors 
HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia. Gut 2012;61:1723-
32. 
40. Park JY, Hong SM, Klimstra DS, et al. Pdx1 expression in pancreatic precursor 
lesions and neoplasms. Appl Immunohistochem Mol Morphol 2011;19:444-9. 
41. Rose SD, Swift GH, Peyton MJ, et al. The role of PTF1-P48 in pancreatic acinar 
gene expression. J Biol Chem 2001;276:44018-26. 
42. Miyatsuka T, Kaneto H, Shiraiwa T, et al. Persistent expression of PDX-1 in the 
pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes 
Dev 2006;20:1435-40. 
43. Liou GY, Doppler H, Necela B, et al. Macrophage-secreted cytokines drive 
pancreatic acinar-to-ductal metaplasia through NF-kappaB and MMPs. J Cell 
Biol 2013;202:563-77. 
44. Murtaugh LC, Keefe MD. Regeneration and repair of the exocrine pancreas. 
Annu Rev Physiol 2015;77:229-49. 
45. Greer RL, Staley BK, Liou A, et al. Numb regulates acinar cell dedifferentiation 
and survival during pancreatic damage and acinar-to-ductal metaplasia. 
Gastroenterology 2013;145:1088-1097.e8. 
46. Zhou Q, Melton DA. Pancreas regeneration. Nature 2018;557:351-358. 
47. Hidalgo-Sastre A, Brodylo RL, Lubeseder-Martellato C, et al. Hes1 Controls 
Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal 
Adenocarcinoma in a Mouse Model. The American journal of pathology 
2016;186:2934-2944. 
48. Wang W, Friedland SC, Guo B, et al. ARID1A, a SWI/SNF subunit, is critical 
to acinar cell homeostasis and regeneration and is a barrier to transformation 
and epithelial-mesenchymal transition in the pancreas. Gut 2019;68:1245-1258. 
49. Fendrich V, Esni F, Garay MV, et al. Hedgehog signaling is required for 
effective regeneration of exocrine pancreas. Gastroenterology 2008;135:621-31. 
50. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. 
Oncogene 2007;26:3279-90. 
51. Collins MA, Yan W, Sebolt-Leopold JS, et al. MAPK signaling is required for 
References                                                          89                                                                                                                                                                                                                                                 
dedifferentiation of acinar cells and development of pancreatic intraepithelial 
neoplasia in mice. Gastroenterology 2014;146:822-834.e7. 
52. Payne SN, Maher ME, Tran NH, et al. PIK3CA mutations can initiate pancreatic 
tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis 
2015;4:e169. 
53. Elghazi L, Weiss AJ, Barker DJ, et al. Regulation of pancreas plasticity and 
malignant transformation by Akt signaling. Gastroenterology 2009;136:1091-
103. 
54. Heid I, Lubeseder-Martellato C, Sipos B, et al. Early requirement of Rac1 in a 
mouse model of pancreatic cancer. Gastroenterology 2011;141:719-30, 730 e1-
7. 
55. Liou GY, Doppler H, DelGiorno KE, et al. Mutant KRas-Induced Mitochondrial 
Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive 
Formation of Pancreatic Precancerous Lesions. Cell Rep 2016;14:2325-36. 
56. Liou GY, Doppler H, Braun UB, et al. Protein kinase D1 drives pancreatic acinar 
cell reprogramming and progression to intraepithelial neoplasia. Nat Commun 
2015;6:6200. 
57. Sawey ET, Johnson JA, Crawford HC. Matrix metalloproteinase 7 controls 
pancreatic acinar cell transdifferentiation by activating the Notch signaling 
pathway. Proc Natl Acad Sci U S A 2007;104:19327-32. 
58. Morton JP, Timpson P, Karim SA, et al. Mutant p53 drives metastasis and 
overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U 
S A 2010;107:246-51. 
59. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 
pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc 
Natl Acad Sci U S A 2006;103:5947-52. 
60. Kojima K, Vickers SM, Adsay NV, et al. Inactivation of Smad4 accelerates 
Kras(G12D)-mediated pancreatic neoplasia. Cancer Res 2007;67:8121-30. 
61. Lerch MM, Gorelick FS. Models of acute and chronic pancreatitis. 
Gastroenterology 2013;144:1180-93. 
62. Siveke JT, Lubeseder-Martellato C, Lee M, et al. Notch signaling is required for 
exocrine regeneration after acute pancreatitis. Gastroenterology 2008;134:544-
55. 
63. Jensen JN, Cameron E, Garay MV, et al. Recapitulation of elements of 
embryonic development in adult mouse pancreatic regeneration. 
Gastroenterology 2005;128:728-41. 
64. Morris JPt, Cano DA, Sekine S, et al. Beta-catenin blocks Kras-dependent 
reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin 
Invest 2010;120:508-20. 
65. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a 
nutrient-sensitive complex that signals to the cell growth machinery. Cell 
2002;110:163-75. 
66. Kim DH, Sarbassov DD, Ali SM, et al. GbetaL, a positive regulator of the 
rapamycin-sensitive pathway required for the nutrient-sensitive interaction 
References                                                          90                                                                                                                                                                                                                                                 
between raptor and mTOR. Mol Cell 2003;11:895-904. 
67. Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated 
inhibitor of the mTORC1 protein kinase. Mol Cell 2007;25:903-15. 
68. Vander Haar E, Lee SI, Bandhakavi S, et al. Insulin signalling to mTOR 
mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007;9:316-23. 
69. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor 
frequently overexpressed in multiple myeloma cells and required for their 
survival. Cell 2009;137:873-86. 
70. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin 
(mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 
through their TOR signaling (TOS) motif. J Biol Chem 2003;278:15461-4. 
71. Schalm SS, Fingar DC, Sabatini DM, et al. TOS motif-mediated raptor binding 
regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 
2003;13:797-806. 
72. Yang H, Rudge DG, Koos JD, et al. mTOR kinase structure, mechanism and 
regulation. Nature 2013;497:217-23. 
73. Long X, Lin Y, Ortiz-Vega S, et al. Rheb binds and regulates the mTOR kinase. 
Curr Biol 2005;15:702-13. 
74. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard 
controlling cell growth. Biochem J 2008;412:179-90. 
75. Xie J, Proud CG. Signaling crosstalk between the mTOR complexes. 
Translation (Austin) 2014;2:e28174. 
76. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor 
mediates a metabolic checkpoint. Mol Cell 2008;30:214-26. 
77. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response 
to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes 
Dev 2004;18:2893-904. 
78. Feng Z, Hu W, de Stanchina E, et al. The regulation of AMPK beta1, TSC2, and 
PTEN expression by p53: stress, cell and tissue specificity, and the role of these 
gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 
2007;67:3043-53. 
79. Kim E, Goraksha-Hicks P, Li L, et al. Regulation of TORC1 by Rag GTPases 
in nutrient response. Nat Cell Biol 2008;10:935-45. 
80. Sancak Y, Peterson TR, Shaul YD, et al. The Rag GTPases bind raptor and 
mediate amino acid signaling to mTORC1. Science 2008;320:1496-501. 
81. Holz MK, Ballif BA, Gygi SP, et al. mTOR and S6K1 mediate assembly of the 
translation preinitiation complex through dynamic protein interchange and 
ordered phosphorylation events. Cell 2005;123:569-80. 
82. Dorrello NV, Peschiaroli A, Guardavaccaro D, et al. S6K1- and betaTRCP-
mediated degradation of PDCD4 promotes protein translation and cell growth. 
Science 2006;314:467-71. 
83. Pende M, Um SH, Mieulet V, et al. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal 
lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA 
translation and reveal a mitogen-activated protein kinase-dependent S6 kinase 
References                                                          91                                                                                                                                                                                                                                                 
pathway. Mol Cell Biol 2004;24:3112-24. 
84. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: 
a novel two-step mechanism. Genes Dev 1999;13:1422-37. 
85. Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by 
mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 
2008;8:224-36. 
86. Ben-Sahra I, Howell JJ, Asara JM, et al. Stimulation of de novo pyrimidine 
synthesis by growth signaling through mTOR and S6K1. Science 
2013;339:1323-8. 
87. Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory 
network downstream of mTOR complex 1. Mol Cell 2010;39:171-83. 
88. Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through 
direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132-41. 
89. Roczniak-Ferguson A, Petit CS, Froehlich F, et al. The transcription factor 
TFEB links mTORC1 signaling to transcriptional control of lysosome 
homeostasis. Sci Signal 2012;5:ra42. 
90. Settembre C, Zoncu R, Medina DL, et al. A lysosome-to-nucleus signalling 
mechanism senses and regulates the lysosome via mTOR and TFEB. Embo j 
2012;31:1095-108. 
91. Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC 
components raptor, rictor, or mLST8 reveals that mTORC2 is required for 
signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006;11:859-
71. 
92. Lamming DW, Mihaylova MM, Katajisto P, et al. Depletion of Rictor, an 
essential protein component of mTORC2, decreases male lifespan. Aging Cell 
2014;13:911-7. 
93. Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/PKB 
phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 
2006;16:1865-70. 
94. Pearce LR, Huang X, Boudeau J, et al. Identification of Protor as a novel Rictor-
binding component of mTOR complex-2. Biochem J 2007;405:513-22. 
95. Liu P, Gan W, Chin YR, et al. PtdIns(3,4,5)P3-Dependent Activation of the 
mTORC2 Kinase Complex. Cancer Discov 2015;5:1194-209. 
96. Zinzalla V, Stracka D, Oppliger W, et al. Activation of mTORC2 by association 
with the ribosome. Cell 2011;144:757-68. 
97. Yang G, Murashige DS, Humphrey SJ, et al. A Positive Feedback Loop between 
Akt and mTORC2 via SIN1 Phosphorylation. Cell Rep 2015;12:937-43. 
98. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls 
the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-
8. 
99. Li X, Gao T. mTORC2 phosphorylates protein kinase Czeta to regulate its 
stability and activity. EMBO Rep 2014;15:191-8. 
100. Gan X, Wang J, Wang C, et al. PRR5L degradation promotes mTORC2-
mediated PKC-delta phosphorylation and cell migration downstream of 
References                                                          92                                                                                                                                                                                                                                                 
Galpha12. Nat Cell Biol 2012;14:686-96. 
101. Thomanetz V, Angliker N, Cloetta D, et al. Ablation of the mTORC2 component 
rictor in brain or Purkinje cells affects size and neuron morphology. J Cell Biol 
2013;201:293-308. 
102. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of 
Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101. 
103. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR 
complex integrity and regulates Akt phosphorylation and substrate specificity. 
Cell 2006;127:125-37. 
104. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls 
hydrophobic motif phosphorylation and activation of serum- and 
glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008;416:375-85. 
105. Efeyan A, Zoncu R, Chang S, et al. Regulation of mTORC1 by the Rag GTPases 
is necessary for neonatal autophagy and survival. Nature 2013;493:679-83. 
106. Kuma A, Hatano M, Matsui M, et al. The role of autophagy during the early 
neonatal starvation period. Nature 2004;432:1032-6. 
107. Mori H, Inoki K, Opland D, et al. Critical roles for the TSC-mTOR pathway in 
beta-cell function. Am J Physiol Endocrinol Metab 2009;297:E1013-22. 
108. Shigeyama Y, Kobayashi T, Kido Y, et al. Biphasic response of pancreatic beta-
cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol 
2008;28:2971-9. 
109. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial 
regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. 
Nat Cell Biol 2001;3:1014-9. 
110. Bentzinger CF, Romanino K, Cloetta D, et al. Skeletal muscle-specific ablation 
of raptor, but not of rictor, causes metabolic changes and results in muscle 
dystrophy. Cell Metab 2008;8:411-24. 
111. Lee PL, Tang Y, Li H, et al. Raptor/mTORC1 loss in adipocytes causes 
progressive lipodystrophy and fatty liver disease. Mol Metab 2016;5:422-432. 
112. Hagiwara A, Cornu M, Cybulski N, et al. Hepatic mTORC2 activates glycolysis 
and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 
2012;15:725-38. 
113. Zheng Y, Collins SL, Lutz MA, et al. A role for mammalian target of rapamycin 
in regulating T cell activation versus anergy. J Immunol 2007;178:2163-70. 
114. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell 
differentiation. Nature 2009;460:108-12. 
115. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo 
differentiation of CD4+Foxp3+ cells. J Exp Med 2008;205:565-74. 
116. Lipton JO, Sahin M. The neurology of mTOR. Neuron 2014;84:275-91. 
117. Crunkhorn S. mTOR inhibition curbs colorectal cancer. Nature Reviews Drug 
Discovery 2015;14:15-15. 
118. Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast 
cancer progression, drug resistance, and treatment. Cancer Metastasis Rev 
2016;35:515-524. 
References                                                          93                                                                                                                                                                                                                                                 
119. Tan FH, Bai Y, Saintigny P, et al. mTOR Signalling in Head and Neck Cancer: 
Heads Up. Cells 2019;8. 
120. Chen H, Zhou L, Wu X, et al. The PI3K/AKT pathway in the pathogenesis of 
prostate cancer. Front Biosci (Landmark Ed) 2016;21:1084-91. 
121. Mann KM, Ying H, Juan J, et al. KRAS-related proteins in pancreatic cancer. 
Pharmacol Ther 2016;168:29-42. 
122. Faller WJ, Jackson TJ, Knight JR, et al. mTORC1-mediated translational 
elongation limits intestinal tumour initiation and growth. Nature 2015;517:497-
500. 
123. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and 
Disease. Cell 2017;169:361-371. 
124. Agarwal S, Bell CM, Taylor SM, et al. p53 Deletion or Hotspot Mutations 
Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and 
Rheb. Mol Cancer Res 2016;14:66-77. 
125. Grabiner BC, Nardi V, Birsoy K, et al. A diverse array of cancer-associated 
MTOR mutations are hyperactivating and can predict rapamycin sensitivity. 
Cancer Discov 2014;4:554-63. 
126. Guertin DA, Stevens DM, Saitoh M, et al. mTOR complex 2 is required for the 
development of prostate cancer induced by Pten loss in mice. Cancer Cell 
2009;15:148-59. 
127. Werfel TA, Wang S, Jackson MA, et al. Selective mTORC2 Inhibitor 
Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 
2018;78:1845-1858. 
128. Schmidt KM, Hellerbrand C, Ruemmele P, et al. Inhibition of mTORC2 
component RICTOR impairs tumor growth in pancreatic cancer models. 
Oncotarget 2017;8:24491-24505. 
129. Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian 
protein that binds to FKBP12 in a rapamycin-dependent fashion and is 
homologous to yeast TORs. Cell 1994;78:35-43. 
130. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is 
mediated by mTORC2 loss and uncoupled from longevity. Science 
2012;335:1638-43. 
131. Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced 
gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 
study. J Clin Oncol 2013;31:3935-43. 
132. Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced 
hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized 
clinical trial. Jama 2014;312:57-67. 
133. Fenner M, Oing C, Dieing A, et al. Everolimus in patients with multiply 
relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-
arm, open-label multicenter trial (RADIT) of the German Testicular Cancer 
Study Group. J Cancer Res Clin Oncol 2019;145:717-723. 
134. Geiger JL, Bauman JE, Gibson MK, et al. Phase II trial of everolimus in patients 
with previously treated recurrent or metastatic head and neck squamous cell 
References                                                          94                                                                                                                                                                                                                                                 
carcinoma. Head Neck 2016;38:1759-1764. 
135. Javle MM, Shroff RT, Xiong H, et al. Inhibition of the mammalian target of 
rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II 
studies. BMC Cancer 2010;10:368. 
136. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of 
the mammalian target of rapamycin pathway with everolimus: a phase I tumor 
pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 
2008;26:1603-10. 
137. Kang SA, Pacold ME, Cervantes CL, et al. mTORC1 phosphorylation sites 
encode their sensitivity to starvation and rapamycin. Science 2013;341:1236566. 
138. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target 
of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J 
Biol Chem 2009;284:8023-32. 
139. Palm W, Park Y, Wright K, et al. The Utilization of Extracellular Proteins as 
Nutrients Is Suppressed by mTORC1. Cell 2015;162:259-270. 
140. Rangwala R, Chang YC, Hu J, et al. Combined MTOR and autophagy inhibition: 
phase I trial of hydroxychloroquine and temsirolimus in patients with advanced 
solid tumors and melanoma. Autophagy 2014;10:1391-402. 
141. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al. mTOR kinase 
inhibition causes feedback-dependent biphasic regulation of AKT signaling. 
Cancer Discov 2011;1:248-59. 
142. Abella JV, Galloni C, Pernier J, et al. Isoform diversity in the Arp2/3 complex 
determines actin filament dynamics. Nat Cell Biol 2016;18:76-86. 
143. Nolen BJ, Pollard TD. Insights into the influence of nucleotides on actin family 
proteins from seven structures of Arp2/3 complex. Mol Cell 2007;26:449-57. 
144. Rouiller I, Xu XP, Amann KJ, et al. The structural basis of actin filament 
branching by the Arp2/3 complex. J Cell Biol 2008;180:887-95. 
145. Goley ED, Rodenbusch SE, Martin AC, et al. Critical conformational changes 
in the Arp2/3 complex are induced by nucleotide and nucleation promoting 
factor. Mol Cell 2004;16:269-79. 
146. Rodal AA, Sokolova O, Robins DB, et al. Conformational changes in the Arp2/3 
complex leading to actin nucleation. Nat Struct Mol Biol 2005;12:26-31. 
147. LeClaire LL, 3rd, Baumgartner M, Iwasa JH, et al. Phosphorylation of the 
Arp2/3 complex is necessary to nucleate actin filaments. J Cell Biol 
2008;182:647-54. 
148. Laurila E, Savinainen K, Kuuselo R, et al. Characterization of the 7q21-q22 
amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator 
of cell migration and invasion in pancreatic cancer. Genes Chromosomes 
Cancer 2009;48:330-9. 
149. Rauhala HE, Teppo S, Niemela S, et al. Silencing of the ARP2/3 complex 
disturbs pancreatic cancer cell migration. Anticancer Res 2013;33:45-52. 
150. Iwaya K, Oikawa K, Semba S, et al. Correlation between liver metastasis of the 
colocalization of actin-related protein 2 and 3 complex and WAVE2 in 
colorectal carcinoma. Cancer Sci 2007;98:992-9. 
References                                                          95                                                                                                                                                                                                                                                 
151. Semba S, Iwaya K, Matsubayashi J, et al. Coexpression of actin-related protein 
2 and Wiskott-Aldrich syndrome family verproline-homologous protein 2 in 
adenocarcinoma of the lung. Clin Cancer Res 2006;12:2449-54. 
152. Iwaya K, Norio K, Mukai K. Coexpression of Arp2 and WAVE2 predicts poor 
outcome in invasive breast carcinoma. Mod Pathol 2007;20:339-43. 
153. Kong B, Wu W, Cheng T, et al. A subset of metastatic pancreatic ductal 
adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced 
hyperactive mTOR signalling. Gut 2016;65:647-57. 
154. Kong B, Cheng T, Wu W, et al. Hypoxia-induced endoplasmic reticulum stress 
characterizes a necrotic phenotype of pancreatic cancer. Oncotarget 
2015;6:32154-60. 
155. Cheng T, Jian Z, Li K, et al. In vivo functional dissection of a context-dependent 
role for Hif1alpha in pancreatic tumorigenesis. Oncogenesis 2016;5:e278. 
156. Driscoll DR, Karim SA, Sano M, et al. mTORC2 Signaling Drives the 
Development and Progression of Pancreatic Cancer. Cancer Res 2016;76:6911-
6923. 
157. van der Kammen R, Song JY, de Rink I, et al. Knockout of the Arp2/3 complex 
in epidermis causes a psoriasis-like disease hallmarked by hyperactivation of 
transcription factor Nrf2. Development 2017;144:4588-4603. 
158. Tyanova S, Temu T, Sinitcyn P, et al. The Perseus computational platform for 
comprehensive analysis of (prote)omics data. Nat Methods 2016;13:731-40. 
159. Beres TM, Masui T, Swift GH, et al. PTF1 is an organ-specific and Notch-
independent basic helix-loop-helix complex containing the mammalian 
Suppressor of Hairless (RBP-J) or its paralogue, RBP-L. Mol Cell Biol 
2006;26:117-30. 
160. Storz P. Acinar cell plasticity and development of pancreatic ductal 
adenocarcinoma. Nat Rev Gastroenterol Hepatol 2017;14:296-304. 
161. Cheng T, Zhang Z, Jian Z, et al. Ductal obstruction promotes formation of 
preneoplastic lesions from the pancreatic ductal compartment. Int J Cancer 
2019;144:2529-2538. 
162. Wu CY, Carpenter ES, Takeuchi KK, et al. PI3K regulation of RAC1 is required 
for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology 
2014;147:1405-16 e7. 
163. Blanchoin L, Amann KJ, Higgs HN, et al. Direct observation of dendritic actin 
filament networks nucleated by Arp2/3 complex and WASP/Scar proteins. 
Nature 2000;404:1007-11. 
164. Robinson RC, Turbedsky K, Kaiser DA, et al. Crystal structure of Arp2/3 
complex. Science 2001;294:1679-84. 
165. Goley ED, Welch MD. The ARP2/3 complex: an actin nucleator comes of age. 
Nat Rev Mol Cell Biol 2006;7:713-26. 
166. Messal HA, Alt S, Ferreira RMM, et al. Tissue curvature and apicobasal 
mechanical tension imbalance instruct cancer morphogenesis. Nature 
2019;566:126-130. 
167. Morrison MM, Young CD, Wang S, et al. mTOR Directs Breast Morphogenesis 
References                                                          96                                                                                                                                                                                                                                                 
through the PKC-alpha-Rac1 Signaling Axis. PLoS Genet 2015;11:e1005291. 
168. Morrison Joly M, Williams MM, Hicks DJ, et al. Two distinct mTORC2-
dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast 
Cancer Res 2017;19:74. 
169. Bompard G, Caron E. Regulation of WASP/WAVE proteins: making a long 
story short. J Cell Biol 2004;166:957-62. 
170. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation 
in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a 
combination of mutant-enriched polymerase chain reaction analysis and allele-
specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54. 
171. Kong B, Wu W, Cheng T, et al. A subset of metastatic pancreatic ductal 
adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced 
hyperactive mTOR signalling. Gut 2016;65:647-57. 
172. Benitz S, Regel I, Reinhard T, et al. Polycomb repressor complex 1 promotes 
gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal 
metaplasia and pancreatic cancer cells. Oncotarget 2016;7:11424-33. 
173. Kong B, Bruns P, Behler NA, et al. Dynamic landscape of pancreatic 
carcinogenesis reveals early molecular networks of malignancy. Gut 
2018;67:146-156. 
174. Qu C, Konieczny SF. Pancreatic Acinar Cell 3-Dimensional Culture. Bio Protoc 
2013;3. 
175. Fleming Martinez AK, Storz P. Mimicking and Manipulating Pancreatic Acinar-
to-Ductal Metaplasia in 3-dimensional Cell Culture. J Vis Exp 2019. 
176. Kühbandner S, Brummer S, Metzger D, et al. Temporally controlled somatic 
mutagenesis in smooth muscle. Genesis 2000;28:15-22. 
177. Zhang YJ, Duan Y, Zheng XF. Targeting the mTOR kinase domain: the second 
generation of mTOR inhibitors. Drug Discov Today 2011;16:325-31. 
178. Basu B, Krebs MG, Sundar R, et al. Vistusertib (dual m-TORC1/2 inhibitor) in 
combination with paclitaxel in patients with high-grade serous ovarian and 
squamous non-small-cell lung cancer. Ann Oncol 2018;29:1918-1925. 
179. MacDonald A, Scarfe G, Magirr D, et al. Phase I study of orally administered 
(14)Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase 
inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics 
in patients with advanced solid malignancies. Cancer Chemother Pharmacol 
2019;83:787-795. 
180. Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton 
in cancer metastasis. Br J Pharmacol 2014;171:5507-23. 
181. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-
mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96. 
182. Heer NC, Martin AC. Tension, contraction and tissue morphogenesis. 
Development 2017;144:4249-4260. 
183. Svitkina T. The Actin Cytoskeleton and Actin-Based Motility. Cold Spring Harb 
Perspect Biol 2018;10. 
184. Amann KJ, Pollard TD. The Arp2/3 complex nucleates actin filament branches 
References                                                          97                                                                                                                                                                                                                                                 
from the sides of pre-existing filaments. Nat Cell Biol 2001;3:306-10. 
185. Mullins RD, Heuser JA, Pollard TD. The interaction of Arp2/3 complex with 
actin: nucleation, high affinity pointed end capping, and formation of branching 
networks of filaments. Proc Natl Acad Sci U S A 1998;95:6181-6. 
186. Mogilner A, Oster G. Force generation by actin polymerization II: the elastic 
ratchet and tethered filaments. Biophys J 2003;84:1591-605. 
187. De P, Aske JC, Dey N. RAC1 Takes the Lead in Solid Tumors. Cells 2019;8. 
188. Ridley AJ, Paterson HF, Johnston CL, et al. The small GTP-binding protein rac 
regulates growth factor-induced membrane ruffling. Cell 1992;70:401-10. 
189. Yoon C, Cho SJ, Chang KK, et al. Role of Rac1 Pathway in Epithelial-to-
Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric 
Adenocarcinoma. Mol Cancer Res 2017;15:1106-1116. 
190. Gulhati P, Bowen KA, Liu J, et al. mTORC1 and mTORC2 regulate EMT, 
motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling 
pathways. Cancer Res 2011;71:3246-56. 
191. Chen Z, Borek D, Padrick SB, et al. Structure and control of the actin regulatory 
WAVE complex. Nature 2010;468:533-8. 
192. Dummler B, Ohshiro K, Kumar R, et al. Pak protein kinases and their role in 
cancer. Cancer Metastasis Rev 2009;28:51-63. 
193. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and 
vesicle trafficking. Trends Cell Biol 2006;16:522-9. 
194. Campellone KG, Welch MD. A nucleator arms race: cellular control of actin 
assembly. Nat Rev Mol Cell Biol 2010;11:237-51. 
195. Hassan Z, Schneeweis C, Wirth M, et al. MTOR inhibitor-based combination 
therapies for pancreatic cancer. Br J Cancer 2018;118:366-377. 







PDAC Pancreatic ductal adenocarcinoma 
SPNs Solid-pseudopapillary neoplasms 
PanNETs Pancreatic neuroendocrine tumors 
PanINs Pancreatic intraepithelial neoplasias 
MCNs Mucinous cystic neoplasms 
IPMNs Intraductal papillary mucinous neoplasms 
GEMMs Genetically engineered mouse models 
LBD Ligand-binding domain 
ER Estrogen receptor 
AFP Autofluorescent proteins 
FACS Fluorescence-activated cell sorting 
ADM Acinar-to-ductal metaplasia 
TGF-α Transforming growth factor-α 
HGF Hepatocyte growth factor 
MMP-9 Matrix-degrading metalloproteinases-9 
Hh Hedgehog 
MAPK Mitogen-activated protein kinase 
GTPase Guanosine triphosphatase 
mROS Mitochondrial reactive oxygen species 
CCK Cholecystokinin 
mTOR Mechanistic target of rapamycin 
PIKK PI3K-related kinase 
mTORC1 mTOR complex 1 
mTORC2 mTOR complex 2 
Rptor Regulatory-associated protein of mTOR 
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mLST8 Mammalian lethal with Sec13 protein 8 
PRAS40 Proline-rich Akt substrate of 40 kDa 
DEPTOR DEP domain-containing mTOR-interacting protein 
TSC Tuberous Sclerosis Complex 
IGF-1 Insulin/insulin-like growth factor-1 
S6K p70S6 Kinase  
4EBP eIF4E Binding Protein 
SREBP Sterol responsive element binding protein 
CAD Carbamoyl-phosphate synthetase 
Rictor Rapamycin insensitive companion of mTOR 
SGK Serum- and glucocorticoid-induced protein kinase 
Arp2/3 Actin-related protein 2/3 
NPFs Nucleation-promoting factors 
ADF Actin depolymerizing factor 
p-MLC2 Phospho-myosin light chain 2 
CHX Cycloheximide 
ICAM-1 Intercellular adhesion morlecule-1 
TNF Tumor necrosis factor 
KEGG Kyoto encyclopedia of genes and genomes 
PCR Polymerase chain reaction 
3D Thress-dimentional 
RFP Red fluorescent protein 
IHC Immunohistochemistry 
IF Immunofluorescence 
WB Western blot 
QRT-PCR 
PFA 
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NC Nitrocellulose 
KRAS Kirsten rat sarcoma viral oncogene homolog 
CDKN2A Cyclin-dependent kinase inhibitor 2A 
TP53 Tumor protein p53 
SMAD4 Small mothers against decapentaplegic 
TGF-β Transforming growth factor-β 
PI3K Phosphoinositide 3-kinase 
Rac1 Rac family small GTPase 1 
PKD1 Polycystic kidney disease 1 
NF-κB Nuclear factor kappa-light-chain-enhancer of 
activated B cells 
EGFR Epidermal growth factor receptor 
ADAM17 A disintegrin and metalloptroteinase-17 
Rheb Ras homolog enriched in brain 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol 3,4,5 trisphosphate 
PDK1 Pyruvate dehydrogenase kinase 1 
eIF4B Eukaryotic translation initiation factor 4B 
PDCD4 Programmed Cell Death 4 
eIF4E Eukaryotic translation initiation factor 4E 
eIF4F Eukaryotic initiation factor 4F 
HIF1α Hypoxia-inducible factor 1 
ULK1 Unc-51-like kinase 1 
TFEB Transcription factor EB 
mSin1 Mammalian stress-activated protein kinase interacting 
protein 1 
Protor1/2 Protein observed with rictor 1 and 2 
PH Pleckstrin homology 
PKCα Protein kinase C alpha 
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Rho Rhodopsin 
Aldh1a3 Aldehyde dehydrogenase 1 family member A3 
Krt19 Keratin 19  
CHX Cycloheximide 
PAK p21-activated kinase 
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